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Multiple sclerosis (MS) is a complex autoimmune disease of the central nervous 
system. Current available treatments can slow down the disease progression in the 
majority of patients, but can neither stop the progression nor cure the patients. MS is 
a debilitating neurological disease of young adults and it affects 0.1% of the 
populations of Northern European descent. The prevalence of MS varies globally 
and locally, and there are several isolated high-risk populations. One such high-risk 
population is in the Southern Ostrobothnia region of Finland, where the incidence 
and prevalence are approximately twice those of the surrounding regions. Both 
environmental and genetic factors are thought to contribute to disease pathogenesis. 
Twin, half-sib and adoption studies all point towards underlying genetic factors that 
predispose to MS. In recent years, genome-wide association studies have revealed 
over fifty genes that are associated with MS. At the start of this thesis project, only 
one MS locus, HLA-DRB1, was known, whilst shortly after the start two more loci, 
IL2RA and IL7R, were reported.  
The aim of this thesis was to find new associated loci, confirm newly found loci 
and assess the relevance of these known loci within the Southern Ostrobothnian 
high-risk isolate, and in the Finnish population overall. The association analyses 
were performed using genome-wide association analysis methods, haplotype 
analysis and meta-analysis methods. In the first study, 68 Southern Ostrobothnian 
cases and 136 identity-by-state matched controls were analyzed in a genome-wide 
association analysis, where an association signal from the SNP rs744166 in the 
STAT3 gene was discovered. The association signal was replicated in an 
international sample set of 4487 MS cases and 9778 controls (OR 1.18, 95% CI 
1.12-1.24, p=2.75×10-10). In order to further understand the association signal, a 
haplotype analysis was performed, revealing that the association signal was on a 
common haplotype. Further, in a genome-wide homozygosity analysis, excess 
homozygosity was found in the 68 cases compared to the 136 controls in three 
genomic loci, 1q42.12, 2q24.3 and 12q24.33. The importance of these loci requires 
further study. 
The second study aimed to replicate loci that had previously been observed to 
associate with MS in an international genome-wide meta-analysis. Three SNPs in 
three loci, IRF8, TNFRSF1A and CD6, were genotyped in 608 trios, 8439 MS cases, 
and 9280 controls from 11 populations of European origin, replicating the 
associations in all three loci. The SNP in IRF8 was strongly associated with MS, 
while the SNPs in TNTRSF1A and CD6 indicated slightly weaker association. The 
odds ratios for all the three loci were similarly modest: IRF8 OR 1.11, TNFRSF1A 
OR 1.12, and CD6 OR 1.11. 
Since the prevalence and incidence of MS is two-fold in the Southern 
Ostrobothnian region and there is evidence for founder effect, the aim of the last 
study was to assess the accumulation of recently identified genome-wide significant 
MS-associated common risk alleles in the Southern Ostrobothnian isolate MS cases 
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and in familial samples. However, we could not detect accumulation of common 
variants in the isolate region or in the families compared to general Finnish samples 
or non-familial samples.  
 
Keywords: genome-wide association, multiple sclerosis, autoimmunity, meta-




This study was carried out at the Institute for Molecular Medicine FIMM, University 
of Helsinki, and at the Public Health Genomics Unit at the National Institute for 
Health and Welfare (THL, former KTL). I would like to acknowledge professor Olli-
Pekka Kallioniemi, the director of FIMM, Pekka Puska, the director of the National 
Institute of Health and Welfare (THL) and Anu Jalanko, the Head of Public Health 
Genomics unit in THL, for providing an excellent and inspiring working 
environment.  
I would like to acknowledge the Helsinki Biomedical Graduate Program, The 
Sigrid Jusélius Foundation, the Emil Aaltonen Foundation, the Biomedicum Helsinki 
Foundation, The Research Foundation of Helsinki University Central Hospital 
(EVO), the Neuropromise EU project and the University of Helsinki Foundation of 
Medicine for providing financial support, that made this thesis possible. 
Thank you for all the MS patients, who have participated in this study. I wish to 
thank the Finnish clinicians, who have made the study possible together with the 
patients: Pentti Tienari, Keijo Koivisto, Irina Elovaara, Mauri Reunanen, Ilkka 
Rautakorpi and late Tuula Pirttilä. In addition, I would like to acknowledge the 
Finnish cohorts Young Finns, Health2000, Jaakko Kaprio and the TWIN cohort, 
Helsinki Birth Cohort Study and all the people involved for collaboration. And thank 
you for all the countless clinicians, technicians, PIs and students in the collaboration 
efforts. The study samples for this effort have been collected from patients and 
controls from Finland, Sweden, Norway, Denmark, United Kingdom, United States, 
Belgium, France, Italy, Spain, Germany, Netherlands and Switzerland. 
I sincerely wish to thank Professor Paolo Gasparini for accepting the invitation to 
be the opponent at my thesis defense. Professor Hannes Lohi and Professor Marju 
Orho-Melander are acknowledged for their review of this thesis. I sincerely value 
your constructive comments that have improved this work. In addition, I would like 
to acknowledge the honored custos, Professor Seppo Meri. I warmly thank my 
wonderful thesis committee that has both supported and instructed me: Iiris Hovatta, 
Samuli Ripatti and Maija Wolf. 
The greatest thanks to my supervisors, Janna Saarela, Aarno Palotie and Leena 
Peltonen. When I started as a genotyping specialist at the Finnish Genome Center 
(FGC) in 2004, I had no idea where the road would take me. I was fortunate to be 
recruited to do a pro gradu with Leena and Janna, who later became my PhD thesis 
supervisors. Leena was a spectacular lady, whose piercing intellect, catching 
enthusiasm, energy and talent for collaboration was inspiring. Fashion, good looks, 
intellect and cutting edge science were all combined in Leena. She pushed me and 
others to go beyond our perceived limits and she opened the world to me. She truly 
was inspirational.  
Janna, has been the supervisor, who has supported and encouraged me 
throughout the thesis. You have been the senior, PI and "science big sister", who has 
 9 
gently guided my way. Your office door has always been open, and you have given 
support when I needed it.  
I wish to thank Aarno for being my second supervisor after Leena's passing. You 
have been involved in the MS project and provided your time, help and effort in a 
very generous way. I thank you for the discussions about the weird ideas, the 
opportunities and doors you have opened for me and the care with which you have 
supervised. 
I wish to thank the senior scientists and the PIs at FIMM and at the THL 
department: Samuli Ripatti for numerous consultations on statistics, William Hennah 
for the endless discussions about the future, science and genetics, Elisabet Widén, 
Kaisa Silader for invaluable help with laboratory and genotyping, Teppo Varilo for 
the work on the pedigrees, Markus Perola, Ismo Ulmanen, Marjo Kestilä and Anu 
Loukola. Life at the university or the institute is full of practicalities, also impossible 
ones. My sincerest thanks to the secretaries Sari Kivikko, Tuija Koski, Heidi Arling 
Tripepi, Susanna Rosas, Riitta Alatalo, Sanni Hyppönen, Riitta Koskinen and Marja 
Medina for all your help. 
All I have learned about the lab work has been from the wonderful laboratory 
technicians at the department. I sincerely thank Minna Suvela, Elli Kempas, Anne 
Nyberg, Liisa Arala, Anne Vikman, Anu Yli-Perttula, Sirkku Ekström, Siv 
Knaappila and other laboratory personnel for your invaluable help. Whenever the 
Tecan has crashed, or the spotter has been too intimidating, you have been there to 
help and guide. Thank you Päivi Lahermo, Mari Kaunisto and others form the FIMM 
Technology center, Minttu Sauramo, Päivi Laiho and colleagues from the DNA unit 
and all others.  
Missukat: Ansku, Eve, Anu, Suvi, and our OA member Annu. Thank you for the 
sauna evenings, the discussions and memorable moments. You have made this 
journey worthwhile. 
My special thanks to the coffee break group and the Cambridge division: Anu, 
Anni, Annu, Ansku, Antti, Diane, Emmi, Hanski, Heidi, Helena, Himanshu, Ida, 
Jaakko, Jarkko, Johannes & co., Jonna, Juho, Jussi, Jonas, Kakku, Kati & Jouni, 
Luca, Mari, Marika, Marine, Marjis, Liisa, Olli, Peter, P-P, Pietari, Saana, Tea, Tero, 
Tiia, Verneri, Will and all others: thank you for the weird discussions, conference 
trips and wild parties. You have created an exceptional(ly hilarious) working and 
after-work environment. I wish all the best for all of you and wish to meet all of you 
again. I have had great times with you guys. 
Thank you for my non-science friends: thank you tykkisiskot, extracurricular 
friends, Conitea friends, and all others. You keep reminding me of how much there 
is in life, besides work. Thank you, my parents, for your support, skills that you have 
given me and for the foundation. Thank you Anna, for being there, although you 
could not care less about science. You have given me another perspective. And 
finally, Johannes, thank you for being there for me and standing by me for better or 





Acknowledgements ................................................................................................ 8 
Contents ................................................................................................................ 10 
List of original publications ................................................................................. 12 
Abbreviations ....................................................................................................... 13 
1 Introduction ................................................................................................. 15 
2 Review of the literature ............................................................................... 16 
2.1 Complex disease genetics ................................................................... 16 
2.1.1 Characteristics of the human genome ............................................. 16 
2.1.2 Gene mapping approaches ............................................................. 20 
2.1.3 Population structure and population isolates ................................. 25 
2.2 Autoimmunity and multiple sclerosis ................................................ 27 
2.2.1 Autoimmunity .................................................................................. 28 
2.2.2 The immune cells in autoimmunity ................................................. 29 
2.2.3 Multiple sclerosis – clinical characteristics ..................................... 32 
2.3 Genetics of complex autoimmune disorders ...................................... 37 
3 Aims of the study ......................................................................................... 41 
4 Materials and methods ................................................................................ 42 
4.1 Study cohorts ...................................................................................... 42 
4.1.1 Finnish study cohorts ...................................................................... 42 
4.1.2 International study cohorts ............................................................. 44 
4.2 Genotyping methods ........................................................................... 47 
4.3 Statistical methods .............................................................................. 49 
4.3.1 Study I: Genome-wide association study in a Southern 
Ostrobothian isolate .................................................................................... 49 
 11 
4.3.2 Study II: Meta-analysis of international replication cohorts .......... 52 
4.3.3 Study III: Genetic burden analysis in families and in the 
Southern Ostrobothnian isolate .................................................................. 52 
5 Results and discussion ................................................................................ 54 
5.1 Association between variants in STAT3 and MS, Study I .................. 54 
5.1.1 Association between common haplotypes in STAT3 and MS ......... 58 
5.1.2 Three regions of homozygosity in MS ............................................ 60 
5.1.3 Copy-number variants in MS patients ............................................ 61 
5.2 Meta-analysis of association between rs1800693 
(TNFRSF1A), rs17445836 (IRF8) and rs17824933 (CD6) and MS, 
Study II ............................................................................................................. 61 
5.3 Accumulation of common MS associated alleles in Southern 
Ostrobothnia, Study III .................................................................................... 63 
5.3.1 Genetic burden score of MS associated alleles was not 
increased in the Southern Ostrobothian isolate ......................................... 63 
5.3.2 No evidence for accumulation of common MS associated 
alleles in Finnish multiplex families ........................................................... 65 
6 Conclusions and future prospects ............................................................... 67 
Web-based resources ........................................................................................... 69 
References ............................................................................................................ 70 
 
12 
LIST OF ORIGINAL PUBLICATIONS 
This thesis is based on the following publications: 
 
I Jakkula E1, Leppä V1, Sulonen A-M, Varilo T, Kallio S, Kemppinen A, 
Purcell S, Koivisto K, Tienari P, Sumelahti M-L, Elovaara I, Pirttilä T, 
Reunanen M, Aromaa A, Oturai AB, Søndergaard HB, Harbo HF, 
Mero I-L, Gabriel SB, Mirel DB, Hauser SL, Kappos L, Polman C, De 
Jagger PL, Hafler DA, Daly MJ, Palotie A, Saarela J, Peltonen L 
(2010) Genome-wide association study in a high-risk isolate for 
multiple sclerosis reveals associated variants in STAT3 gene. American 
Journal of Human Genetics 86(2):285-91 
 
II International Multiple Sclerosis Genetics Consortium2 (2011) The 
genetic association of variants in CD6, TNFRSF1A and IRF8 to 
multiple sclerosis: a multicenter case-control study. PLoS ONE 
6(4):e18813 
 
III Leppä V, Jakkula E, Ripatti S, Gourraud PA, Kaprio J, Eriksson J, 
Lehtimäki T, Koskinen S, Palotie A, Saarela J (2012) Genetic Burden 
of Common Variants in a Population Isolate and in MS families  
submitted 
 
The publications are referred to in the text by their roman numerals.  
These articles are reproduced with the kind permission of their copyright holders. 
 
1 The authors contributed equally to this work 
2 First consortium author and corresponding author. Consortium authors: Leppä V, 
Surakka I, Tienari P, Elovaara I, Compston A, Sawcer S, Robertson N, De Jager PL, 
Aubin C, Hafler DA, Oturai AB, Søndergaard HB, Sellebjerg F, Sørensen PS, 
Hemmer B, Cepok S, Winkelmann J, Wichmann H-E, Comabella M, Bustamante 
MF, Montalban X, Olsson T, Kockum I, Hilert J, Alfredsson L, Goris A, Dubois B, 
Mero I-L, Smestad C, Celius EG, Harbo HF, D’Alfonso S, Bergamaschi L, Leone 
M, Ristori G, Kappos L, Hauser SL, Cornu-Rebeix I, Fontaine B, Boonen S, Polman 




ANZgene Australia and New Zealand Multiple Sclerosis Genetics Consortium 
BWH Boston Women's Hospital 
EAE experimental autoimmune encephalomyelitis 
CD Crohn’s disease 
CD6 CD6 molecule 
CEU People of Northern and Western European ancestry, Utah, USA  
 (HapMap population) 
CHB Han Chinese, Beijing, China (HapMap population) 
CHR chromosome 
CI confidence interval 
CNS central nervous system 
DNA deoxyribonucleic acid 
EDSS Expanded Disability Status Scale 
e.g. exempli gratia 
GWAS genome-wide association study 
HLA human leukocyte adhesion 
IBD identical by descent 
IBS identical by state 
IL2RA interleukin 2 receptor, alpha 
IL7R interleukin 7 receptor  
IMSGC International Multiple Sclerosis Genetics consortium 
IRF8 interferon regulatory factor 8  
JPT Japanese, Tokyo, Japan (HapMap population) 
LD linkage disequilibrium 
mRNA messenger ribonucleic acid 
MAF minor allele frequency 
MRI magnetic resonance imaging  
MS multiple sclerosis 
OMIM Online Mendelian Inheritance in Man 
OR odds ratio 
PCR  polymerase chain reaction 
PPMS primary progressive multiple sclerosis 
RA rheumatoid arthritis 
RNA ribonucleic acid 
ROH region of homozygosity 
RRMS relapsing - remitting multiple sclerosis 
SCID severe combined immunodeficiency 
SD standard deviation 
SLE systemic lupus erythematosus 
SNP single nucleotide polymorphism 
SO Southern Ostrobothnia 
14 
SPMS secondary progressive multiple sclerosis 
STAT3 Signal Transducer and Activator of Transcription 3 
STAT5a signal transducer and activator of transcription 5A 
STAT5b signal transducer and activator of transcription 5B 
TNFRSF1A tumor necrosis factor receptor precursor  
TRAPS tumor necrosis factor receptor-associated periodic syndrome 
T1D type 1 diabetes 
UC ulcerative colitis 






Multiple sclerosis (MS) is a chronic complex autoimmune disorder of the central 
nervous system. MS patients develop multiple plaques in their central nervous 
system, where the axons of neurons have been demyelinated (Lucchinetti et al., 
2000). Symptoms can vary according to the extent and location of the demyelination. 
There is no cure for MS and the disease can lead to disability and sometimes death 
(Kurtzke, 1983, Bronnum-Hansen et al., 2004, Koch-Henriksen et al., 1998, 
Sadovnick et al., 1992, Sumelahti et al., 2002, Roxburgh et al., 2005). Although the 
age of onset for MS varies greatly, most patients receive their diagnosis of definite 
MS between 20 and 45 years of age (Hammond et al., 1988).  
MS is considered to be an important debilitating neurological disease of the 
central nervous system in young adults. The prevalence of MS is approximately one 
in a thousand individuals in the Finnish population (Sumelahti et al., 2001), which is 
similar to the prevalence in other populations of Northern European descent 
(Bentzen et al., 2010, Benedikz et al., 2002, Dahl et al., 2004, Forbes et al., 1999, 
Ford et al., 1998, Grytten et al., 2006, McGuigan et al., 2004, Sarasoja et al., 2004, 
Sumelahti et al., 2001). In the Southern Ostrobothnia region of Finland, the 
prevalence and incidence of MS is approximately two-fold that of the surrounding 
regions (Sumelahti et al., 2000). There is evidence for a founder effect in this region 
(Tienari et al., 2004), which suggests the accumulation of unknown heritable factors.  
MS is a complex disease: both environmental and genetic factors are thought to 
affect the predisposition (Ebers et al., 1986, Hansen et al., 2005, Sadovnick et al., 
1996). So far, the etiology of MS is largely unknown. Only a few environmental 
factors have been identified to contribute to MS predisposition despite intensive 
research (Riise et al., 2003, Haahr et al., 1995, Kim et al., 2000, Munger et al., 
2004).  
The genetic studies have had more success. Linkage and association at the HLA-
DRB1 locus on chromosome 6p was first published in 1972 (Jersild et al., 1972) and 
the risk allele has a reasonably high odds ratio (OR 2-3) (Sawcer et al., 2011). 
Recent genome-wide association studies (GWAS) and the following meta-analyses 
have identified at least 54 loci (ANZgene, 2009, IMSGC, 2007, Jakkula et al., 2010, 
Jersild et al., 1972, Mero et al., 2009, Patsopoulos et al., 2011, Sanna et al., 2010). 
Before this thesis project, only three MS loci were known: HLA-DRB1, IL2RA 
and IL7R (IMSGC, 2007, Jersild et al., 1972). The aim of this thesis was to identify 
new loci for MS, replicate recently identified MS loci, and evaluate the accumulation 
of the recently identified MS loci in the Finnish population, especially in the high-
risk isolate and patients with a familial background for MS. 
 
Review of the literature 
16 
2 REVIEW OF THE LITERATURE 
2.1 Complex disease genetics 
The phenomenon of inheritance of traits has been known for thousands of years and 
has been used to breed domestic animals and cultivate plants. The studies of Gregor 
Mendel clarified the laws of inheritance and defined modes of inheritance for 
monogenic traits. However, most traits are neither monogenic nor strictly ruled by 
the genes. In complex traits many genetic loci act together and with environmental 
factors to create complex phenotypes.  
The recognition of deoxyribonucleic acid (DNA) polymer as the molecular base 
of inheritance, and the discovery of its three dimensional structure in 1953, 
facilitated the birth of the field of genetics (Watson and Crick, 1953). The human 
genome consists of approximately 3.2 billion base pairs, packed into 22 pairs of 
autosomal chromosomes and one pair of sex determining chromosomes (XX or XY). 
One of the sister chromosomes from each pair is from the mother, and the other from 
the father.  
At each generation, or gamete formation, one of the two sister chromosomes 
from each pair is selected to the gametes, and to offspring, randomly. During gamete 
formation, the sister chromosomes align in the first cell division and can recombine 
or exchange their genetic material in a crossing-over event (Figure 1). 
Recombination creates new combinations of variants, breaks old connections and 
gives rise to unique chromosomes, which creates new possibilities for genetic 
variation to make new phenotypes or new phenotype combinations. 
2.1.1 Characteristics of the human genome 
The first draft of the sequence of the human genome was launched in 2001 and the 
first complete version was launched in 2004 (Lander et al., 2001, Venter et al., 2001, 
International Human Genome Sequencing Consortium, 2004). The human genome 
project discovered that only 1.1-3% of the genome is protein coding with the number 
of protein coding genes estimated to be only around 21,000 (Clamp et al., 2007, 
Venter et al., 2001, Harrow et al., 2012). In addition to the protein coding sequence, 
the human genome contains functional elements, such as regulatory elements, 
structural elements and ribonucleic acid (RNA) genes, such as micro-RNA (miRNA) 
coding genes, and sequence of unknown functions (Lindblad-Toh et al., 2005, Siepel 
et al., 2005).  
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Figure 1 Recombination. The diploid nucleus of one cell (A) is divided into four haploid 
gametes during gametogenesis (D). B) The chromosomes first replicate and create a copy of 
themselves that remains attached at the centromere. Then the chromosomes align with their 
homologous pair during metaphase. At this time, the chromosomes can form chiasmata, or 
sites where the chromosomes cross over (the green and the blue chromosome), and can 
exchange material. C) Next, the chromosomes are divided into daughter cells. D) These cells 
then divide once more so that the sister chromatides are pulled into separate cells. The 
recombinant chromosomes (with both green and blue) carry new allele combinations not 
present in either of the original chromosomes.  
Genetic Variation 
Mutations are the source of genetic variation, and variation is the key to inherited 
phenotypic flexibility and alteration. The probability of a mutation per base pair per 
generation is 1.2-2.5×10-8 (Nachman and Crowell, 2000, 1000 Genomes Project 
Consortium, 2010). This means that each individual is expected to carry 
approximately 30 - 60 de novo germline mutations, on average, compared to the 
parents. The number of germline mutations is affected by the age of parents (Sanders 
et al., 2012), and majority of de novo mutations originate from the father (O'Roak et 
al., 2012). 
The genetic variation can be roughly divided into nucleotide sequence and 
structural variation in DNA. Single base pair polymorphisms (SNPs) represent the 
sequence variation, where the number of bases stays the same, but the sequence is 
different. SNPs are usually biallelic and they are very common in the human genome 
(Figure 2). On average 1 in every 1000 bases is expected to be variable in a human 
genome due to SNPs (1000 Genomes Project Consortium, 2010). Another source of 
variation is structural variation. It includes small changes in base pair compositions, 
such as insertion-deletion polymorphisms of one to a few bases (indels) or copy 
number variation (CNV) of larger segments of DNA (Figure 2). In October 2012, 
there were more than 38 million SNPs and indels in the dbSNP database. The 
structural variations have a large size scale from 1bp (indels) to millions of base 
pairs (large CNVs).  
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Figure 2 Genetic variation. Panel A presents a single nucleotide polymorphism (SNP), where 
one base pair (A) in the sequence has been mutated into another (G) in another sequence. 
Panel B presents an indel, where one or a few base pairs have been inserted or deleted 
compared to the other sequence. Panel C presents a VNTR, specifically a short 
microsatellite, where different sequences can have different number of short sequence 
repeats, here either 4 or 5 'CA' repeats. Finally, panels D and E present CNVs. Panel D 
presents a deletion, where a segment of DNA is missing compared to the reference 
sequence. Panel E presents a duplication of the same segment. 
CNVs are much rarer but contribute to an additional 0.4% difference in DNA 
sequence between any two individuals (Redon et al., 2006, Sebat et al., 2004) 
(Figure 2). 
The current massive parallel next generation sequencing techniques (NGS) allow 
the investigation of entire individual genomes at the base pair level. The 1000 
genomes project uses NGS to find rare variants and it aims to discover most of the 
human variation with at least 1% minor allele frequency (MAF) (1000 Genomes 
Project Consortium, 2010). Therefore, the NGS projects will increase the number of 
known genetic variants substantially. 
Structural repeat sequences such as the variable number of tandem repeats or 
VNTRs include the abundant micro- and minisatellites that are sequential repeats of 
1-4 and 5 to ~ a dozen nucleotides, respectively. They can have phenotypic 
consequences, such as Huntington disease (Huntington's Disease Collaborative 
Research Group, 1993) or fragile X syndrome (Kremer et al., 1991), but are thought 
to be mostly neutral and have been used as genetic markers in gene mapping. 
Transposons and retrotransposons are mobile elements in the genome that can 
create variation in the human genome by moving or copying genomic material from 
one location to another. In addition, they can act as sites for non-allelic homologous 
recombination that can cause misalignment of the genome and create, for example, 
CNVs. The majority of the human transposable elements are thought to be stable and 
inactive (Djebali et al., 2012), but some are still active and are thought to be able to 
move or copy DNA from one location to another. The biallelic SNPs are the most 
commonly used genomic markers because of their abundance, easy genotyping and 
stability, but the microsatellites are still used, for example, in forensic and paternity 
testing because of they are multiallelic and highly informative. 
It is expected that most of the variation in the genome is rare (<1% MAF) and 
has not had the time to rise in frequency or to disappear from the population (1000 
Genomes Project Consortium, 2010, Keinan and Clark, 2012). However, some 
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ancient variants, that are mostly expected to be neutral, and therefore are not 
subjected to selection, have become common over the course of human population 
history. An international effort, The HapMap consortium, has catalogued common 
SNP variation and ancestral haplotypes that are present in the human populations. 
Most common SNPs with >5% MAF are thought to be present in all populations, but 
in some occasions a variant can rise to high frequency in one population but not in 
others (Pickrell et al., 2009, Xing et al., 2009, Rosenberg et al., 2002). In some 
instances there has been selection either for or against a variant, but more often the 
population-specific rise in frequency is thought to be caused by drift. Two well 
known examples of positive selection are the variants that encode the lactase 
persistence (Tishkoff et al., 2007) and malaria resistance phenotypes (Ayodo et al., 
2007).  
Genome regulation and dynamics 
The genome is a dynamic structure that is differentially expressed and regulated in 
different cells and tissues: approximately 22% of the genome is transcribed in each 
cell line, and no cell line expresses more than 57% of all the observed transcripts 
(Djebali et al., 2012). The expression of genes or transcription of DNA has many 
layers of regulation. The activity of the proteins that are involved in the transcription 
is regulated by external factors and environmental signals. The access of 
transcription factors to the regulatory regions can be altered by methylation of CpG 
islands or histone modifications that regulate the packaging of DNA (Birney et al., 
2007). In addition, the expression of genes can be regulated in many ways during 
translation, for example, microRNAs (miRNA) can alter the half-life of the protein 
coding messenger-RNAs (Pasquinelli et al., 2000).  
Variants in transcription factor binding sites, miRNA coding sites, miRNA 
binding sites, methylation sites, or histone modifications can affect gene and genome 
regulation. These variations and modifications can affect, for example, gene 
expression, gene-environment interactions, and genome accessibility, and they can 
be tissue specific (Dimas et al., 2009, Xiong et al., 2011, Du et al., 2009, Fire et al., 
1998, Reinhart et al., 2000, Gervin et al., 2012, He et al., 2012). These types of 
variations could have more subtle effects than direct protein sequence affecting 
DNA-alterations. The regulatory variation in the human genome is under intensive 
research and many sites of tissue-specific regulatory sites have been discovered 
using the correlations and combinations of SNP genotypes and gene expression data 
(Dimas et al., 2009). For example, alleles of the SNP rs2867316 on chromosome 17 
are correlated with the expression levels of EFTUD2 in T cells, but not in fibroblasts 
(Dimas et al., 2009). The SNPs that correlate with gene expression are called 
expression quantitative trait locus (eQTL) SNPs (Dimas et al., 2009).  
The Encyclopedia of DNA Elements (ENCODE) project was founded to identify 
all functional regions of the human genome, including all regions of transcription, 
transcription factor binding sites, chromatin structure, chromatin accessibility, gene 
expression and RNA processing, non-coding RNA species, DNA methylation and 
histone modification, among others (Encode Project Consortium et al., 2012). The 
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efforts of the ENCODE Project Consortium have revealed that at least 62% of the 
genome is transcribed into RNA, including non-polyadenylated RNAs (Djebali et al., 
2012). The ENCODE project has also discovered, novel non-coding RNAs (Howald 
et al., 2012, Djebali et al., 2012), novel exons in known genes (Howald et al., 2012), 
potential novel protein coding genes and transcripts, novel gene isoforms, decrease 
in the intergenic regions, and an increasing overlap between protein coding regions, 
which might create a need to reconsider the concept of a gene (Djebali et al., 2012). 
In addition, the ENCODE project has revealed that at least 80% of the genome is 
involved in at least one biochemical function in at least one cell type, such as 
transcription, methylation, DNA regulation, histone modification or transcription 
factor binding (Encode Project Consortium et al., 2012). This is assumed to be the 
lower limit, since the study did not assess all cell types or transcription factors, and 
cell lines have specific active sites, active transcription factor binding sites and cell 
specific expression patterns (Djebali et al., 2012, Encode Project Consortium et al., 
2012).  
2.1.2 Gene mapping approaches 
Heritability 
Traits or phenotypes that have a heritable component can be subjected to gene 
mapping. The proportion of the genetic effect on a phenotype is usually described 
using heritability. Heritability is a mathematical estimate of the proportion of the 
total phenotypic variance of a trait in a population that can be explained by genetic 
factors. In humans, heritability is usually calculated from the phenotypic 
concordance of monozygotic (MZ) and dizygotic (DZ) twins, who share 100% or 
50% of their genomes, respectively. MZ twins essentially share their entire genome, 
and therefore phenotypic differences between MZ twins can be expected to be 
largely caused by environmental effects (Merriman, 1924, Liew et al., 2005, 
Siemens, 1924, Galton, 1876). 
Linkage analysis 
Linkage analysis was the first genome-wide method for positional cloning, or gene 
mapping (Morton, 1955). It is a pedigree based method to map trait affecting loci. 
Linkage analysis follows the co-segregation of a trait and a marker in a pedigree in 
large chromosomal segments (Figure 3). Markers that are close to the trait affecting 
locus are linked with it, and appear to be co-segregated. Recombination events break 
the connections between the markers and the trait over generations, and this is used 
to narrow down the locus of interest on the chromosome. Linkage studies have been 
successful in mapping monogenic traits but the results in complex disease mapping 
have been discouraging. Most linkage results in complex diseases have not been 
replicated in subsequent studies. The challenges in linkage studies in complex 
diseases are thought to be due to multiple reasons, for example, locus heterogeneity, 
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Figure 3 Linkage. Panel A represents monogenic autosomal recessive inheritance with full 
penetrance, where two causal alleles are required for a trait (individual 21). In panel B the 
inheritance pattern is monogenic autosomal dominant, and individuals carrying a segment of 
the yellow chromosome have the trait. Chromosomes are presented as colorful lines under 
each individual. Grand-parents chromosomes (01-04) are passed on to the grand children 
(21-24) through parents (11-12). Males are represented as squares and females as circles. 
Individuals with the trait are indicated with solid black shapes. 
incomplete penetrance, small sample size, and no clear pattern of inheritance 
(Altmuller et al., 2001, Risch, 2000). It has been pointed out, that association studies 
and linkage studies have the power to detect very different type of connections 
between a phenotype and genetic variation. 
Linkage disequilibrium and association studies can be used to map genes 
Let's consider a mutation that has occurred on an ancestral chromosome in the 
proximity of another variant. If the subsequent recombination events and mutations 
in the following generations have not had time to separate the two markers in most 
genomes, the two markers appear together more often than would be expected by 
chance, which is to say they are non-randomly segregated in a population 
(Thompson and Neel, 1997). These two markers are said to be in linkage 
disequilibrium (LD) (Thompson and Neel, 1997, Maniatis et al., 2002). Markers that 
are in LD reside on the same chromosome and are usually close to one another 
physically (Peterson et al., 1995). LD can be used to identify ancestral haplotypes, 
i.e. blocks of DNA that are shared in the population and have been inherited from a 
common ancestor. From an evolutionary perspective, recombination gradually 
breaks the ancestral chromosomes into shorter segments in the subsequent 
generations eroding the connection between markers (International HapMap 
Consortium, 2005). Linkage disequilibrium can be measured using the correlation 
between genetic markers in a population with each haplotype recognized by a 
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distinctive set of marker alleles (Johnson et al., 2001, International HapMap 
Consortium, 2005). In a given population at a given time, there usually exist a 
limited number of common ancestral haplotypes (with MAF > 5%) that can be 
identified by genotyping common SNPs (Johnson et al., 2001, International HapMap 
Consortium, 2005).  
The International HapMap consortium launched a project in 2003 to create a 
catalogue of common variation and haplotype structure within human populations. 
The first version of the HapMap data was released in 2005 (International HapMap 
Consortium, 2005). The availability of dense marker maps and LD information has 
facilitated the association studies, especially genome-wide association studies 
(GWAS) (International HapMap Consortium, 2005). Common haplotype variation in 
the human genome can be tagged by using from 300,000 to 1,000,000 SNP markers, 
depending on the desired haplotype frequencies and the extent of LD in the 
population of interest (Gabriel et al., 2002, Kruglyak, 1999). The haplotype map can 
be used to predict LD between markers in a population and to estimate haplotypes 
without any knowledge of parental chromosomes (International HapMap 
Consortium, 2005, Chapman et al., 2003). The HapMap project revealed that the 
length of LD differs between populations and the ancestral haplotypes are shorter in 
the more diverse populations of African descent. The median haplotype length in 
populations of European or Asian origin is expected to be ~44 kb, but only ~22 kb in 
African populations (Gabriel et al., 2002). This reflects the bottle necks in the non-
African populations, where the recombination events have not yet had time to break 
down the ancestral haplotypes. 
Genetic association studies 
Association analysis tests the statistical dependence between one or more 
phenotypes and genetic polymorphisms (Gabriel et al., 2002, International HapMap 
Consortium, 2005). In association studies, the tested markers (usually SNPs) are 
often selected based on LD, to tag as much regional genetic variation as possible 
with as few markers, or polymorphisms, as possible (Johnson et al., 2001). The 
polymorphisms are then genotyped and the statistical dependence between the 
genotypes and the phenotype is measured statistically. Association is considered 
significant if the likelihood of falsely rejecting the null hypothesis is less than 5% (p-
value < 0.05).  
Association studies can be performed in population cohorts, by comparing 
unrelated cases and controls, using family-based association analyses or combined 
studies. Family based studies can use, for example, transmission-disequilibrium test 
(TDT) that can test for genetic linkage in the presence of association (Spielman et 
al., 1993). Combined studies can use both families and independent cases and 
controls (Hiekkalinna et al., 2011). In general, association studies can be divided into 
two categories: candidate gene studies and genome-wide association studies. 
Candidate gene association studies are generally based on information from previous 
linkage analyses or on biological function of gene products. The candidate gene 
region is tagged with genetic markers and analyzed for association. There have been 
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many candidate gene studies in complex disease genetics, but few loci have been 
successfully replicated in independent follow-up studies. This could be due to 
several reasons, for example, unsuccessful choice of candidate genes, focusing on 
genes and not including regulatory regions, inadequate sample size, or population 
stratification. 
In genome-wide association analysis, genetic markers (usually SNPs) are 
selected to cover the entire genome in an as unbiased way as possible. In the case of 
GWAS from hundreds of thousands to millions of markers are tested. Current 
genotyping platforms use microarrays that can hold up to 4.5 million probes for SNP 
and copy-number variation detection, and a single array can be used to genotype up 
to four samples. Multiple testing is especially notable in GWAS, but it needs to be 
considered in all studies, including candidate gene studies. 
Since multiple testing increases the risk of false positive findings, or by chance 
observations, of a p-value less than 0.05, the level of significance needs to be 
readjusted (Risch and Merikangas, 1996). Methods for correcting for multiple testing 
in genetic studies include, for example, Bonferroni correction that considers the 
number of tests, permutation methods for empirical p-values, and the Nyholt method 
that takes into account the LD between the markers (Nyholt, 2004). The limit for a 
significant uncorrected p-value has been calculated to be 5×10-8 in a genome-wide 
association analysis, assuming 1,000,000 independent association tests and 95% 
probability of no false positives (Risch and Merikangas, 1996).  
General applications that arise from the use of LD are haplotype analysis, and 
genotype imputation. Haplotypes can be estimated in populations based on reference 
frequencies and the correlations of genetic polymorphisms (Gabriel et al., 2002, 
Wang et al., 2002). Analysis of haplotypes can be more informative than analyzing 
only single markers, especially for rare variants in LD with the tagging SNPs 
(Johnson et al., 2001, Browning and Browning, 2007, de Bakker et al., 2005). 
Imputation is a method, where the genotypes of ungenotyped markers are 
computationally estimated based on the LD information from variation in a reference 
population (Marchini et al., 2007, Servin and Stephens, 2007). Both of these 
approaches increase the number of genetic markers that can be assessed in the 
analysis. 
Meta-analysis 
Association study results from different populations and study sets can be combined 
using meta-analysis methods (Kazeem and Farrall, 2005, Mantel, 1963). The meta-
analyses combine results across different studies and populations. Therefore, 
different meta-analysis methods exist, that differ from one another, for example, in 
the way they weigh the contribution of each population. These methods can 
generally account for population stratification, caused by differences in allele 
frequencies between populations (Nelis et al., 2009, WTCCC, 2007, Devlin and 
Roeder, 1999, Pritchard et al., 2000, Kazeem and Farrall, 2005, Mantel, 1963). 
Combining association studies increases the sample size, which in turn increases the 
statistical power to detect association signals.  
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Figure 4 Number of new loci identified in GWAS studies has increased from 2005 to October 
12th 2012. The data is from the Catalog of Published Genome-Wide Association Studies 
(https://www.genome.gov/gwastudies/).The year of publication is on the X-axis and the 
number of novel loci reported in that year are shown on the Y-axis. 
Power 
Power is the likelihood of finding a true association or difference of a defined 
magnitude in a data set with a certain number of samples, certain assumed allele 
frequencies, and desired false positive and negative rates. The power of a study 
depends on the number of samples, correct classification of cases and controls, the 
expected odds ratio (OR) or effect size, estimated penetrance, the expected 
frequency of the alleles, and the extent of LD in the population (WTCCC, 2007, 
Zeggini et al., 2008, Buyske et al., 2009). Roughly, the larger these values are, the 
greater the power (WTCCC, 2007). These parameters can compensate for one 
another, with, for example, extensive LD and higher odds ratio in theory making up 
for smaller sample sizes. A good example is genetic mapping in dogs (Wilbe et al., 
2010). Dogs have traits and diseases that run in pedigrees or breeds, and have 
extensive LD due to inbreeding within breeds (Lindblad-Toh et al., 2005). Therefore, 
only 15,000 markers and fewer samples, compared to human studies, are needed to 
map genetic loci (Lindblad-Toh et al., 2005, Wilbe et al., 2010). However, it should 
also be noted that allelic heterogeneity can in some cases lower the power to detect 
associations (Slager et al., 2000). 
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Genome-wide association studies have been effective in finding loci with 
small effect sizes 
The well-powered GWASs have proved to be very efficient in finding common 
variants with small effect sizes in complex diseases (Barrett et al., 2008, WTCCC, 
2007, De Jager et al., 2009b, IMSGC, 2011, Barrett et al., 2009a, Cooper et al., 
2008, Patsopoulos et al., 2011) (Figure 4). However, these individual variants 
explain only a fraction of the heritability of most complex traits. A large portion of 
the heritability remains unexplained despite dozens of identified loci (Visscher, 
2008, Zeggini et al., 2008, Barrett et al., 2008, Manolio et al., 2009). Epistasis, 
structural variation, gene-environment interactions, rare(er) high-impact variants, 
epigenetics, incomplete LD with the detected markers and the causal variant, simply 
more unidentified common low-risk loci, and inaccurate heritability estimates have 
all been speculated to explain some of the missing heritability, amongst others. 
 So far there is some evidence for rare potentially high-impact alleles in some 
common diseases and new more well-powered GWAS studies have increased the 
number of known common low-risk loci (Pinto et al., Sanders et al., Cohen et al., 
2004, Nejentsev et al., 2009, Mero et al., 2009). Epigenetics and genetic interactions 
are under intensive research, but they have been proven to be challenging fields of 
research. 
Next generation sequencing techniques 
The advent of NGS technologies has created new possibilities for the identification 
of rare and de novo variants (Sanders et al., 2012, Neale et al., Girard et al., 2011). 
The costs of sequencing individual genomes at reasonable accuracy and coverage 
have come down enough to allow large-scale sequencing projects. Sequencing 
techniques have already shed light on the autism spectrum disorders, schizophrenia 
and specific cancers (Neale et al., 2012, Sanders et al., 2012, Girard et al., 2011, 
Pasqualucci et al., 2011). The major challenges for NGS are the storage and analysis 
of the massive amounts of data that are generated during the sequencing process, 
alongside the analysis of the vast number of variants identified. These modern 
sequencing techniques have not only opened an avenue for scrutinizing individual 
genomes, but have also allowed the large-scale sequencing of the RNA content, for 
analysis of transcript level modification and regulation, through using RNA-seq 
method, and to identify transcription factor binding sites, by Chip-Seq (Visel et al., 
2009, Ross-Innes et al., 2012, Wilhelm et al., 2008, Steidl et al., 2011). 
2.1.3 Population structure and population isolates 
Population history affects population genetics: it can cause differences in allele 
frequencies and lead to accumulation of disease causing variants and their nearby 
genetic markers (Bersaglieri et al., 2004, Tishkoff et al., 2007, Thompson and Neel, 
1997, Varilo et al., 2003, Savukoski et al., 1994). Therefore, population history 
should be taken into account when selecting research methods. Drift, migration, 
selection, founder effect and other phenomena affect the genetic structure of all 
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populations. Humans have most likely dispersed from Africa to inhabit most of the 
planet and several subsequent migration waves and bottle neck effects have affected 
the genetic structure in human populations (Ramachandran et al., 2005, Tishkoff et 
al., 2009). Therefore, genetic variation is greatest within Africa, while populations 
outside Africa tend to have only a sub-group of the African variation (Conrad et al., 
2006, Ramachandran et al., 2005, Tishkoff et al., 2009).  
Whenever a sub-population has left from an existing habitat to colonize new 
regions, the new population has carried with them only an essentially random subset 
of the existing genetic variation (Conrad et al., 2006, Ramachandran et al., 2005, 
Tishkoff et al., 2009). Similarly, a population that has risen or re-risen from a small 
number of individuals, called founders, carries a subset of the original variation. If a 
small number of individuals establish a population, the population is said to have 
gone through a bottle neck. Human populations, in general, are estimated to have 
less variation than other primates, which is thought to be caused by multiple bottle 
necks throughout the course of human population history (Yu et al., 2004, 
Chimpanzee Sequencing and Analysis Consortium, 2005).  
The frequencies of alleles and variants in a population that has gone through a 
bottle neck, or in populations that have been separated, can differ substantially from 
the population of origin (Price et al., 2009, Norio, 2003a). This is demonstrated in 
the Finnish population with the consequence of the Finnish disease heritage, which is 
the increase of certain diseases in Finland due to inherited factors. At least 35 
globally rare known mono- or oligogenic inherited diseases are known to have 
significantly increased frequency in Finland (Norio, 2003b, Lahtela et al., 2010), 
(www.findis.org). The bottle neck effect can not only cause the increase of a certain 
allele, but it can also decrease the frequency of other alleles and inherited diseases. 
An example of a disease that has become rare in Finland is the autosomal recessive 
disorder phenylketonuria. The prevalence of phenylketonuria is approximately 1:26 
000 of live births in Sweden (Holmgren et al., 1976), 1:17 000 in France (Abadie et 
al., 2001) and 1:10 000 in the UK (Hardelid et al., 2008), but only 1:100 000 in 
Finland (Pastinen et al., 2001). The overall unequal distribution of alleles, like the 
phenylketonuria allele, is called population structure. Population structure can be 
detected both between and within countries or populations, i.e. between people from 
Eastern and Western Finland or European populations (Jakkula et al., 2008, Nelis et 
al., 2009, Price et al., 2009).  
Several populations can be said to be population isolates. Such isolated 
populations are often characterized by having different minor allele frequencies, 
reduced haplotype diversity, and increased LD, compared to the populations of 
origin. (Hovatta et al., 1997, Jakkula et al., 2008, Tienari et al., 2004, Service et al., 
2006, Huyghe et al., 2010b). Isolated populations are often either geographically 
isolated, for example on islands, such as the Sardinian, Icelandic and Orkney 
populations, or linguistically isolated, such as the Saami (Price et al., 2009, Huyghe 
et al., 2010a, Huyghe et al., 2010b, Francalacci et al., 2003). In addition to 
geographically isolated populations, a population isolate can exist without physical 
or linguistic barriers, as is the case in Kuusamo and Southern Ostrobothnia (Jakkula 
et al., 2008, Tienari et al., 2004, Hovatta et al., 1997). The enrichment of certain rare 
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alleles and diseases in, for example Southern Ostrobothnia, is demonstrated by the 
enrichment of a rare monogenic disorder called late infantile neuronal ceroid 
lipofuschinosis in patients with Southern Ostrobothnian ancestry (Norio, 2003b, 
Santavuori et al., 1982). There are also marked differences in the frequency of 
certain complex phenotypes in different regions of Finland. For example, there is 
enrichment of autism in Central Finland compared to the overall Finnish population, 
whilst Southern Ostrobothnia has an increased prevalence in multiple sclerosis (MS) 
(Tienari et al., 2004, Kilpinen et al., 2009). It can be hypothesized, that predisposing 
alleles for these complex diseases could have been enriched in these regions, 
although the effect of environmental factors cannot be excluded. 
In association studies the population structure can create spurious associations 
that are related to the allele frequency differences between populations (or drift) 
rather than the disease status. For example, if the phenotype of interest is more 
frequent in one sub-population, then more phenotype carriers can originate from the 
sub-isolate. If the population structure is not controlled, the markers that are more 
frequent in the high-risk sub-population can appear to be associated with the disease 
independent of the true effect (Pritchard et al., 2000, Clayton et al., 2005). 
Thoroughly matching cases and controls for population of origin, meta-analysis of 
different populations (or sub-populations), and other methods can be used to account 
for the population stratification in order to avoid false positive results (Pritchard et 
al., 2000, Clayton et al., 2005, Price et al., 2006).  
2.2 Autoimmunity and multiple sclerosis 
Humans and other multi-cellular organisms are a living environment and a resource 
for a number of commensal, symbiotic and pathogenic micro-organisms, such as 
bacteria, virus, fungi and parasites. A number of mechanisms have evolved to protect 
humans against harmful micro-organisms, pathogens, and to regulate the commensal 
and symbiotic species. Epithelia are the first line of defense that shields the human 
body from invasion, and a number of epithelial secretions have antimicrobial 
components. Physical barriers are not enough on their own, pathogens can breach 
them and cause infection. When a pathogen has entered the human body, the 
immune system is activated. 
The immune system consists of a number of leucocytes that circulate the human 
body or guard the epi- and endothelia. Their role is to recognize and destroy 
potentially harmful pathogens as well as dangerously altered host self structures, 
such as proto-cancer cells. The immune system uses two major routes to overcome 
the infection: it either removes them directly from the extracellular spaces through 
phagocytosis, or induces controlled cell death, apoptosis, in the invaded or altered 
host cells (Medana et al., 2000, Yannelli et al., 1986). To avoid destruction of the 
healthy normal tissues (self), it is crucial for the immune system to be able to tolerate 
what is self and to recognize the difference between normal self and non-self or 
altered self structures (Nemazee and Buerki, 1989, Nemazee and Burki, 1989, 
Ramsdell and Fowlkes, 1990, Hodes et al., 1989, Fry et al., 1989). 
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2.2.1 Autoimmunity 
Autoimmunity is a phenomenon where the immune system initiates an immune 
response against a normal, usually tolerated, self tissue. Autoimmunity can be 
targeted to a specific tissue or can be more general, depending on the self-structure 
that has been falsely recognized as foreign. In MS the immune system is thought to 
target the myelin around the neuronal axons in the central nervous system, leading to 
the destruction of this insulation, of oligodendrocytes, and damaging the axons 
(Lucchinetti et al., 2000, Reindl et al., 1999, Zamvil et al., 1985) Similarly, in type 1 
diabetes (T1D) the tolerance to the insulin producing β-cells in pancreatic islets of 
Langerhans, is thought to be lost, and thus the β-cells are destroyed. Several islet-
specific auto-antigens have been suggested, including glutamic acid decarboxylase 
(GAD) and insulin (Tisch et al., 1993, Atkinson et al., 1992, Palmer et al., 1983, 
Daniel et al., 1995, Sobel and Creswell, 2006). Systemic lupus erythematosus (SLE) 
is an example of a more general autoimmune disorder where several tissues are 
affected. The auto-antibodies in SLE are thought to be targeted against, for example, 
nuclear components such as DNA and RNA that are present in nearly all cell types, 
which could partly explain the systemic effect (Kamat et al., 2003, Kowal et al., 
2006, Pollak, 1964). In addition to MS, T1D and SLE, several other common 
complex chronic autoimmune disorders exist. For example, rheumatoid arthritis 
(RA) is an autoimmune disorder of the joints and the skin is affected in psoriasis. 
The autoimmune inflammatory bowel diseases can be divided to ulcerative colitis 
(UC), a continuous inflammation of the colonic and rectal mucosal layers, and 
Crohn's disease (CD), a discontinuous transmural inflammation anywhere in the 
gastrointestinal tract. Each of these individual autoimmune diseases have 
prevalences of 0.2-3% in populations of European origin (Kappelman et al., 2007, 
Kurd and Gelfand, 2009, Gelfand et al., 2005, Johnson et al., 1995, Symmons et al., 
2002, Bentzen et al., 2010). 
Common autoimmune susceptibility -hypothesis 
It has been suggested that common complex autoimmune disorders could share 
common factors that predispose to the loss of tolerance, or to an over-reactive 
immune system (Gregsen et al., 2006). According to the hygiene hypothesis, the lack 
of parasites and infections in modern Western societies could contribute to 
autoimmunity (Okada et al., 2010). It has been suggested, that persistent helminth 
infections, in particular, might prevent autoimmunity (Rook et al., 2008). MS, T1D, 
SLE, inflammatory bowel diseases, psoriasis and RA have common elements in 
addition to distinctive features. Some autoimmune disorders accumulate in certain 
families. For example, Grave’s disease, RA, MS and psoriasis have all been reported 
to have a tendency to accumulate in the same families (Broadley et al., 2000, 
McCombe et al., 1990, Midgard et al., 1996). Further, the co-occurrence of MS and 
inflammatory bowel diseases has been suggested, although results are currently 
inconsistent (Broadley et al., 2000). In addition to familial accumulation, 
autoimmune diseases share common features, which have lead to the common 
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autoimmune susceptibility hypothesis (Broadley et al., 2000, McCombe et al., 1990, 
Midgard et al., 1996). 
Several common complex autoimmune diseases, like MS, psoriasis, SLE and 
inflammatory bowel diseases have a sub-type with a relapsing-remitting type of 
disease course (Lublin and Reingold, 1996, Petri et al., 1991, Nevitt and Hutchinson, 
1996, Lapidus et al., 1998). The female to male ratio is often skewed with many 
autoimmune disorders being more common in females (Confavreux and Vukusic, 
2006, Johnson et al., 1995, Symmons et al., 2002). However, this is not always the 
case as, for example, UC seems to be more common in males (Kappelman et al., 
2007). Hormonal regulation has been suggested to be behind the uneven gender 
distribution, since the disease activity seems to be at least partially hormonally 
regulated. Some diseases can ease in women during pregnancy, although this could 
be due to other pregnancy related tolerance mechanisms (Confavreux et al., 1998, de 
Man et al., 2008, Aluvihare et al., 2004, Morgan et al., 2005, Raychaudhuri et al., 
2003). Autoimmune diseases are chronic and there is no cure for any of them at the 
moment although immunosuppressants can be used in some diseases to alleviate 
some of the symptoms (Prisms Study Group and the University of British Columbia, 
2001, Hartung et al., 2002). 
2.2.2 The immune cells in autoimmunity 
The innate immune system 
The immune system can be divided into two major sections: innate and adaptive 
immunity. Both are thought to play a role in autoimmunity. The adaptive immune 
system is capable of creating an effective response against an extensive range of 
specific epitopes or antigens, whereas innate immunity is essential in activating the 
adaptive immunity. The innate immune system is considered to be the first active 
cellular response to pathogens. The innate immune cells carry germline-coded cell-
surface receptors that can recognize a fixed set of non-self structures that are 
common in many pathogens. These receptors include, for example, the Toll-like 
receptors, which have a limited capability for recognition (Lemaitre et al., 1996, 
Rock et al., 1998). Therefore, the innate immune system has a more limited ability to 
detect epitopes. The cell-surface recognition receptors receive the signal that leads to 
activation, proliferation and differentiation of the cells, from their resting state 
precursor cells to their active state (Rock et al., 1998, Lemaitre et al., 1996). The 
major effect of innate immunity on autoimmunity is, in many cases, thought to be 
mediated through antigen presentation. Antigen presenting cells (APCs) are essential 
for the activation of the adaptive immune system (Wilde et al., 1983, Hickey and 
Kimura, 1988, Huitinga et al., 1995, Austyn et al., 1988). The innate immunity 
APCs includes cells with phagocytic activity: dendritic cells, macrophages and 
microglia, amongst others. Microglia are present in the central nervous system 
(CNS), where as the macrophages are mainly present in the periphery. Dendritic 
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cells, in turn, are the major APC type that presents antigens to the adaptive immune 
system. 
Both microglia and macrophages have been observed in MS lesions, and are thus 
considered to be important in MS pathogenesis, having been suggested to clear the 
plaques from debris (Huitinga et al., 1995, Kuhlmann et al., 2002, De Simone et al., 
1995, Takahashi et al., 2007, Weinger et al., 2011). In SLE, inefficient clearance of 
apoptotic cells by macrophages and the subsequent uptake of nuclear material by 
dendritic cells have been suggested to contribute to the disease pathogenesis 
(Baumann et al., 2002, Herrmann et al., 1998, Kenyon et al., 2011). Additionally, the 
depletion of macrophages has been suggested to ameliorate RA and experimental 
autoimmune encephalomyelitis (EAE) in rodents (Li et al., 2012a, Gerritse et al., 
1996). Dendiritic cells are the major APC type. Studies of EAE, a rodent model for 
MS, have shown that myelin specific dendritic cells play an important role in EAE, 
and potentially also in the mouse model of T1D (Subramanian et al., 2001, Hoglund 
et al., 1999) For example, dendritic cells have been found to present neuronal 
antigens in the cervical lymph nodes in both EAE and MS (van Zwam et al., 2009). 
On the other hand, regulatory dendritic cells have been reported to be involved in 
suppression of autoimmune responses, especially in CD (Kwon et al., Rimoldi et al., 
2005). In some autoimmune disorders local microglial production of the complement 
also seems to be active (Dietzschold et al., 1995, Kenyon et al., 2011, Compston et 
al., 1989). 
The adaptive immune system 
The adaptive immune system consists of lymphocytes, which can be divided into 
two major categories, B cells and T cells. The B cells are responsible for the humoral 
immune response, and they produce antibodies against specific targets. The T cells 
can be divided into different groups depending on their function: CD8 carrying 
cytotoxic T cells (CD8+ T cells), CD4 carrying T helper (Th) cells (CD4+ T), and 
CD4+ regulatory T cells (Tregs). The cytokine environment after antigen 
presentation guides the development of naïve CD4+ helper T cells into Th1, Th2 or 
Th17 cells (Harrington et al., 2005). All these cell types secrete a distinctive set of 
cytokines. The adaptive immune cells depend on their recognition receptors called B 
cell receptors (BCR) and T cell receptors (TCR). Each T and B cell carries a unique 
receptor with a unique recognition pattern that defines its activating target. One cell 
is thought to only respond to a specific type of molecular pattern recognized by its 
receptor. However, the vast amount of different cell clones, with their unique 
receptors, creates an immense potential for adaptation. The T and B cells have the 
potential to recognize self antigens through their receptors and launch a strong 
immune attack against the host itself. Therefore, their proliferation, maturation and 
activation are strictly controlled (Nemazee and Buerki, 1989, Ramsdell et al., 1989, 
Hodes et al., 1989). Mechanisms that induce tolerance to the self are an essential part 
of the development of the adaptive immune system (Hodes et al., 1989, Ramsdell et 
al., 1989, Nemazee and Buerki, 1989, Nemazee and Burki, 1989) However, 
quiescent self-reactive T and B cell clones are thought to be present in all 
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individuals, but on rare occasions something can trigger them and this could lead to 
autoimmunity.  
B cells are specialized to produce antibodies, with each B cell clone producing 
one type of antibody that binds to one epitope. B cells produce one class of 
antibodies at a time (IgA, IgG, IgM or IgE) and switch antigen classes in certain 
sequential order. Oligoclonal antibodies against self-antigens have been found in 
many autoimmune diseases (Kowal et al., 2006, Pollak, 1964, Daniel et al., 1995, 
Palmer et al., 1983, Tisch et al., 1993, Reindl et al., 1999, Johnson et al., 2005, 
Rantapaa-Dahlqvist et al., 2003, Tagami et al., 1983, Aoki et al., 1989). In MS, 
oligoclonal immunoglobulin bands are present in the cerebrospinal fluid of patients 
(Delmotte and Gonsette, 1977, Johnson et al., 1977, McDonald et al., 2001). The 
exact nature of these antibodies is unknown, although auto-antibodies against myelin 
basic protein (MBP) and myelin oligodendrocyte glycoprotein (MOG) have been 
found in patients (Reindl et al., 1999, Zhou et al., 2006). B cell activation and 
antibody production usually requires an activation signal from CD4+ Th1 or Th2 
cells, which, in turn, have been activated by APCs or antigen presenting B cells 
(Doyle and Strominger, 1987, McLaughlin and Wucherpfennig, 2008).  
CD4+ T cells use their TCR and accessory molecules to recognize antigens that 
are presented by APC on major histocompatibility complex II (HLA-II) molecules, 
also called human leukocyte antigen complex II. Certain haplotypes of the MHC-II 
locus are known risk factors in MS and in many other autoimmune disorders, which 
makes CD4+ T cells a good candidate cell population for contributing to the 
autoimmune process (Asano et al., 2009, Barrett et al., 2008, WTCCC, 2007, Franke 
et al., 2008b, Franke et al., 2010, Han et al., 2009, Harley et al., 2008, Helms et al., 
2005, Jersild et al., 1972, Nair et al., 2009, Nejentsev et al., 2009, Raychaudhuri et 
al., 2012, IMSGC, 2011, Silverberg et al., 2009, Todd et al., 1987, Wordsworth et 
al., 1989). In MS, the CD4+ T cells have been found in post mortem brain lesions 
and biopsies, and can be used to induce EAE in rodent models (Jones et al., 1999, 
Owhashi and Heber-Katz, 1988). Similar results have been seen in psoriasis 
(Nickoloff and Wrone-Smith, 1999). 
Recent observation of different T cell sub-types in autoimmune disorders has 
directed attention towards Treg and interleukin-17 (IL17) producing Th17 T cell 
sub-populations (Langrish et al., 2005). Myelin specific Th17 cells were shown to 
induce EAE in mice, rather than the initially thought Th1 population (Langrish et al., 
2005). Additionally, Th17 deficient or Th17 inducing IL23 deficient mice have been 
found to be resistant to both EAE and collagen-induced arthritis (CIA), which is a 
rodent model of RA (Nakae et al., 2003, Langrish et al., 2005, Cua et al., 2003, 
Murphy et al., 2003). MS patients have been shown to have a higher number of Th17 
cells in their blood and cerebrospinal fluid, especially during exacerbation 
(Matusevicius et al., 1999). A recent study showed that Th17 regulating miR-326 
was correlated with MS severity (Du et al., 2009).  
Recent studies have emphasized the role of Treg cells in autoimmune diseases 
(Lepault and Gagnerault, 2000, Martinez et al., 2012, Chaudhry et al., 2009). It is 
thought that the Treg cells are responsible for maintaining or inducing the inactive 
state of the autoreactive B and T cells (Jang et al., 2011, Martinez et al., 2012), 
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especially the Th17 cells (Chaudhry et al., 2009). It has been suggested that Treg 
cells would induce anergy in the arthritogenic self-reactive T cells, and that pro-
inflammatory signals in the inflamed joint would induce reduced suppressive 
capability in Tregs (Martinez et al., 2012, van Amelsfort et al., 2007). Tregs have 
been suggested to play a role as anti-autoimmunity regulators, at least in RA, MS, 
UC, and T1D (Lepault and Gagnerault, 2000, Martinez et al., 2012, Chaudhry et al., 
2009).  
Cytotoxic T cells recognize antigens presented on the major histocompatibility 
complex 1 (HLA-I) molecules, also called human leukocyte antigen complex I, that 
present intracellular pathogen antigens on all cells. Upon recognition of the MHC-I – 
antigen complex, they become activated and induce apoptosis in the presenting cell. 
CD8+ T cells have been observed to play an important role in T1D and they are also 
present in MS lesions (Lucchinetti et al., 2011, Babbe et al., 2000, Bulek et al., 
2012). The number of CD8+ T cells and macrophages has been reported to correlate 
with the extent of axon damage (Kuhlmann et al., 2002). Interestingly, myelin 
specific CD8+ T cells have been reported to be able to induce CNS inflammation in 
rodents, although the type of inflammation is different from CD4+ induced EAE 
(Huseby et al., 2001).  
Regulation of the immune system varies in different compartments of the body, 
which could explain some of the differences between autoimmune diseases. The 
gastrointestinal tract immune cells have to tolerate a multitude of non-self antigens, 
especially the commensal microbiota and antigens present through nutrition. 
Therefore, the gut immune system has evolved to induce tolerance against ingested 
antigens. Some studies have even suggested that probiotic supplements could be 
useful in managing autoimmune diseases (Kwon et al., 2010). The other extreme is 
the brain, which is isolated from systemic immunity by the blood brain barrier. 
Immune cells are not known to pass the barrier unless they are activated or during 
inflammation. It has been suggested that one cause leading to MS could be leaking 
of the blood brain barrier. A recent study found support for this hypothesis, reporting 
that Th17 cells could mediate the blood—brain barrier disruption and lead to CNS 
inflammation in MS (Kebir et al., 2007). Despite intensive research, the etiology and 
triggers for autoimmune reactions remain elusive and hard to disentangle. 
2.2.3 Multiple sclerosis – clinical characteristics 
MS is a complex autoimmune disease affecting the central nervous system (CNS). 
Most patients receive a definitive diagnosis of MS between the ages of 20 and 45 
years of age (Hammond et al., 1988). The disease is gradually disabling and is 
potentially debilitating. Disease progression is estimated using the Expanded 
Disability Status Scale (EDSS), ranging from no disability (EDSS 0.0) to death due 
to MS (EDSS 10.0) (Kurtzke, 1983). The multiple sclerosis severity score (MSSS) 
has been developed to assess the severity of the disease, and to predict the level of 
disability later on (Roxburgh et al., 2005). Patients with MS have a decreased life 
expectancy and it has been estimated that 55-70% of patients die of MS related 
causes (Bronnum-Hansen et al., 2004, Koch-Henriksen et al., 1998, Sadovnick et al., 
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1992, Sumelahti et al., 2002, Roxburgh et al., 2005). The severity of MS varies 
greatly from patient to patient. 
Relapsing remitting MS (RRMS) is the most common form of MS, with 
approximately 67-90% of patients initially diagnosed with it (Sumelahti et al., 2002, 
Confavreux and Vukusic, 2006, Dahl et al., 2004, Grytten et al., 2006). The disease 
course in RRMS is episodic with bouts of MS, and worsening of the symptoms, 
followed by partial or complete recovery (Figure 5). In primary progressive MS 
(PPMS) the disease course is a continuous progression from the beginning, without 
bouts or any recovery (Figure 5). Only 9-20% of patients are diagnosed with PPMS 
(Sumelahti et al., 2003, Confavreux and Vukusic, 2006, Dahl et al., 2004, Grytten et 
al., 2006). Approximately two thirds of MS patients with RRMS will later develop 
secondary progressive MS (SPMS), where the initial RRMS disease type turns to 
steady progression (Figure 5) (Lublin and Reingold, 1996). As in other autoimmune 
diseases, the gender distribution in MS patients is uneven. The distribution is 
particularly skewed in patients with RRMS where the female to male ratio is 2-3:1, 
whilst the ratio in PPMS patients is closer to 1:1 (Sumelahti et al., 2003, Hammond 




Table 1. McDonald’s criteria for MS diagnosis for relapsing-remitting MS (RR) and 
primary progressive MS (PP) based on the presence of MS attacks (relapses), lesions in the 
central nervous system, and on the possible presence of oligoclonal bands in the 
cerebrospinal fluid (CSF).  
Disease 
type 
Clinical presentation Additional Evidence Needed 
RR ≥2 attacks and objective evidence for ≥2 
clinical lesions separated in time 
No additional evidence needed 
RR 1 attack and objective evidence for ≥2 
clinical lesions separated in time 
A second clinical attack or, for example, MRI1 evidence for 
dissemination in time 
RR ≥2 attacks and objective evidence for 1 
clinical lesion 
Positive evidence for CSF+2 and evidence for ≥2 lesions in 
the MRI or evidence for dissemination in space in MRI 
RR 1 attack and evidence for 1 clinical lesion MRI evidence for dissemination in time or space or MRI 
evidence for ≥2 lesions and CSF+2 
PP ≥1 year of insidious neurological 
progression suggestive of MS 
Two of the following: evidence for MS in MRI in the brain, 
evidence for MS in MRI in the spinal cord, and CSF+2 
1MRI= magnetic resonance imaging, 2CSF+= oligoclonal immunoglobulin bands present in the 
cerebrospinal fluid. 
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Figure 5 Types of MS progression. The four main types of disease progression in MS are 
divided into relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), primary 
progressive MS (PPMS) and relapsing-progressive MS (RPMS) described according to 
Lublin and Reingold, 1996. 
The first systematic description of MS was by Jean-Martin Charcot, who 
published his observations in a series of publications in 1868. Today, most patients 
are diagnosed using either the Poser or the McDonald criteria (McDonald et al., 
2001, Poser et al., 1983) (Table 1). McDonald criteria is a revised version of the 
Poser criteria. Symptoms in MS can be transient and variable and include, for 
example, dizziness, cognitive dysfunction, spasticity and loss of vision. Therefore, 
receiving a correct diagnosis can take many years, especially for RRMS patients 
(Sumelahti et al., 2002). Current treatments for MS cannot cure or stop the 
progression, but can slow down the disease. 
Pathogenesis 
Multifocal demyelinating inflammation in the CNS is a hallmark of MS and it can be 
observed as plaques using magnetic resonance imaging (MRI). The plaques are 
visible due to loss of myelin, which forms the white matter of the brain. 
Oligodendroctyes are the primary cell type affected by the demyelination, since they 
produce the myelin sheath that is thought to be the target (Lucchinetti et al., 2000). 
The damage is not restricted to the oligodendrocytes, but extends to the axons 
(Kuhlmann et al., 2002). The damage to axons correlates with duration and course of 
the disease (Kuhlmann et al., 2002). It is thought that this compromises the neurons 
ability to conduct signals, causing ephaptic signaling or cross-talk between 
neighboring axons and the various symptoms of MS. 
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Prevalence 
The prevalence of MS in populations of Northern European descent is typically 
around 1-2/1000) (Bentzen et al., 2010, Benedikz et al., 2002, Dahl et al., 2004, 
Forbes et al., 1999, Ford et al., 1998, Grytten et al., 2006, McGuigan et al., 2004, 
Sarasoja et al., 2004, Sumelahti et al., 2001). The prevalence varies around the world 
and correlates with latitude: MS is rare near the Equator and increases towards the 
poles (Hammond et al., 1988, McGuigan et al., 2004, Kurtzke et al., 1979). It has 
been suggested that the gradient is due to environmental factors, such as sun 
exposure or pathogens. Interestingly, however, the Sami populations that inhabit 
northernmost Europe, have been reported to have exceptionally low prevalence of 
MS (Gray et al., 2008). There have been reports of increasing prevalence and 
incidence of MS in recent years, especially in women (Debouverie et al., 2007, 
Granieri et al., 2007, Gray et al., 2008, Grimaldi et al., 2001, Sarasoja et al., 2004, 
Bentzen et al., 2010). This has been speculated to be caused by increased survival, 
more accurate diagnosis and changes in the hormonal environment in women, for 
example, oral contraceptives and older age at first child birth (Granieri et al., 2007, 
Sarasoja et al., 2004, Bentzen et al., 2010).  
The prevalence varies not only according to latitude, but also within regions and 
countries (Tienari et al., 2004, Rothwell and Charlton, 1998, Bostrom et al., 2009, 
Visser et al., 2012). Certain isolated populations are known to have a notably 
increased prevalence of MS compared to the surrounding populations. The Sardinian 
island in Italy, the Orkney Islands off the coast of Scotland (Visser et al., 2012), the 
Lothian Region of Scotland (Rothwell and Charlton, 1998), Värmland in Sweden 
(Bostrom et al., 2009) and Southern Ostrobothnia in Finland (Tienari et al., 2004) are 
all such populations. It has been speculated, that specific high-risk MS predisposing 
genetic variants could have been enriched in these regions. 
Risk factors for MS 
The etiology of MS remains elusive despite decades of intensive research. At 
present, only a few factors are known to influence MS predisposition. Migration 
studies support the importance of environment in the development of MS (Hammond 
et al., 2000, Ahlgren et al., Dean and Elian, 1997). It has been suggested that child 
migrants acquire the average risk of the population in the new region, whereas, the 
risk of adult migrants would be closer to the population of origin (Dean and Elian, 
1997). However, there have been conflicting results (Hammond et al., 2000). 
Pathogens have been suggested to play a role in MS (Kurtzke and Heltberg, 
2001), but only Epstein-Barr virus and human herpes virus 6 (HHV-6) have shown 
promising results, so far. Epstein-Barr virus, or mononucleosis, has been associated 
with MS in several studies (Haahr et al., 1995, Ascherio et al., 2001, Marrie et al., 
2000). The presence of antibodies against the Epstein-Barr virus has been suggested 
to correlate with disease activity (Farrell et al., 2009). Additionally, the HHV-6 is 
suspected to either affect or exacerbate MS (Kim et al., 2000, Alvarez-Lafuente et 
al., 2006). The precise role of these infectious agents has not yet been resolved. 
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Exposure to sun, especially in childhood, has been shown to decrease the risk of 
MS (van der Mei et al., 2001, Islam et al., 2007, Freedman et al., 2000). This 
beneficial effect has been hypothesized to be linked to both increased vitamin D 
levels and the Treg promoting effects of ultraviolet radiation. While a number of 
studies report the protective effect for vitamin D (Munger et al., 2004, Munger et al., 
2006), others have suggested that the effects of sun exposure and vitamin D could in 
fact be independent (Lucas et al., 2011). Recent genetic studies of MS have found 
associations to genes that are involved in vitamin D metabolism (Ramagopalan et al., 
2011, IMSGC, 2011), but the link between vitamin D, sun exposure and MS still 
needs further studies before definite conclusions can be made. 
Some studies report that smoking increases the risk of MS, but the increase in 
risk is small (relative risk 1.7-1.8) (Riise et al., 2003). However, the subtype of MS 
and the extent of disability correlate with smoking. Smokers are more likely to have 
PPMS than people who have never smoked (Healy et al., 2009).  
Genetic factors contribute to MS predisposition 
Several twin studies in MS have suggested that genetic factors contribute to the 
disease predisposition. The concordance between monozygotic twins has ranged 
from 13 to 34%, whereas the concordance of dizygoic twins has been closer to 2-5% 
(Ebers et al., 1986, Hansen et al., 2005, Islam et al., 2006, Mumford et al., 1994, 
Thorpe et al., 1994). The concordance between siblings is similar to that of the 
dizygotic twins, ~3% (Sadovnick et al., 1996). The prevalence of both twinning and 
MS are low, which means that the number of individuals in these studies has been 
low, and therefore the confidence intervals are large. The estimated heritability (H2) 
from twin studies ranges from 0.25 to 0.76 (Hawkes and Macgregor, 2009). In 
general, the risk of MS is increased in close relatives of MS patients, varying 
proportionally to the fraction of shared genes (Sadovnick et al., 1996, Ebers et al., 
1995).  
Half-sib, family and adoption studies in populations of European descent also 
suggest that inherited factors may contribute to MS predisposition (Ebers et al., 
2000, Ebers et al., 1995, Sadovnick et al., 1996). The risk of MS in adopted 
individuals with affected adoptive family members is similar to the population level 
(Ebers et al., 1995). Multigenerational families with multiple affected family 
members are rare in MS. In Finland and Southern Ostrobothnia there is an 
exceptional level of clustering of MS in families (Wikström et al., 1984), which 




2.3 Genetics of complex autoimmune disorders 
Major common complex autoimmune disorders such as RA, psoriasis, T1D, MS, 
inflammatory bowel diseases and SLE have been intensively studies for decades. 
These diseases have moderate heritability and there have been many linkage and 
association studies that have aimed to identify predisposing genetic factors. Until the 
advent of GWAS, the only established locus in many autoimmune diseases was the 
HLA-locus (Table 2). This has strengthened the view that these diseases are immune-
mediated, because the HLA molecules are essential in antigen presentation and in 
priming adaptive immune responses. In many cases, the HLA risk haplotypes are 
responsible for the strongest known increase in risk. Due to the structure and tight 
LD across the HLA region, the linkage and association signals can cover long 
haplotypes with alleles from multiple HLA genes (de Bakker et al., 2006, Horton et 
al., 2008). 
Many candidate gene studies in autoimmune disorders have been unsuccessful. 
However, at least one exception exists, the insulin gene in T1D (Bell et al., 1984, 
Hakonarson et al., 2007). One major issue in many candidate gene studies has been a 
limited sample size and therefore an inadequate power to detect association. In 
contrast to candidate studies, GWASs with large sample sizes (usually > 1000 
samples) and the following meta-analyses have been very successful in identifying 
associated loci with modest odds ratios (Barrett et al., 2009a, Barrett et al., 2009b, 
Barrett et al., 2008, Okada et al., 2012, Stahl et al., 2010, Patsopoulos et al., 2011, 
IMSGC, 2011). 
 
Table 2. The established HLA loci that have been linked or associated with RA, MS, UC, 
CD, psoriasis and T1D. 




 HLA-DPB1  
Wordsworth et al., 1989, Raychaudhuri et al., 2012 
Multiple sclerosis HLA-DRB1, HLA-A Jersild et al., 1972, IMSGC, 2011 
Ulcerative colitis HLA-DRB1- HLA-
DQB1- HLA-DRA 
Franke et al., 2008b, Silverberg et al., 2009 
Crohn's disease HLA-DQA, HLA-DRA2 Franke et al., 2010, Barrett et al., 2008 
Psoriasis HLA-C Helms et al., 2005, Nair et al., 2009 




Todd et al., 1987, WTCCC, 2007, Nejentsev et al., 
2007, Asano et al., 2009 
SLE HLA-DRB1-HLA-
DQB1-HLA-DRA 
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With the emergence of associated loci in GWAS, it has become clear that many 
of the associated loci in different autoimmune diseases are located near to one 
another or are even at the same loci (Table 3). The effects of the associated alleles of 
SNPs can be opposite, but the loci remain the same (Jakkula et al., 2010, Barrett et 
al., 2008, Cotsapas et al., 2011, Ramos et al., 2011). This has added to the discussion 
about the common autoimmune hypothesis (Cotsapas et al., 2011, Forabosco et al., 
2009, Ramos et al., 2011). There have been genetic studies about autoimmune 
disease predisposing loci, but more comprehensive studies with larger sample sizes 
are needed to identify polymorphisms and pathways that can shed light on the 
biology underlying the common autoimmune phenotype (Cotsapas et al., 2011, 
Ramos et al., 2011). 
So far, 192 genes have been associated at a genome-wide significant level across 
seven autoimmune diseases: RA, psoriasis, SLE, MS, T1D, and the two 
inflammatory bowel diseases (CD and UC). Forty of these loci are associated with 
multiple autoimmune disorders: 25 genes are associated with two autoimmune 
diseases, 10 with three, 5 with four, and one with five (Table 3). Furthermore, there 
is suggestive evidence for some of the involved loci in the remaining autoimmune 
disorders. Most of the genes in these loci have functions in the immune system. 
However, since neither the exact causative variants nor the affected gene(s) are 
definitely known, one should be cautious when interpreting the association results. 
Once analyzed in greater detail it may be found that some of the signals in these 
regions originate from different loci for the different diseases, whilst others are from 
the same loci (Cotsapas et al., 2011). It would seem reasonable to speculate that the 
list of associated genes is likely to grow in the near future and more overlap will 
undoubtedly emerge. 
The SNPs in the five loci that are associated with at least four autoimmune 
disorders are located in or near the following genes: the protein tyrosine 
phosphatase, non-receptor type 22 gene (PTPN22) in the first locus, the tumor 
necrosis factor, the alpha-induced protein 3 (TNFAIP3) and oligodendrocyte 
transcription factor 3 (OLIG3) genes in the second locus, the T-cell activation 
RhoGTPase activating protein gene (TAGAP) in the third locus, the v-rel 
reticuloendtheliosis viral oncogene homolog (REL) and the pseudouridylate synthase 
10 genes (PUS10) in the fourth locus, and the ORM1-like 3 (S. cerevisiae) 
(ORMDL3) and the IKAROS family zinc finger 3 (Aiolos) genes (IKZF3) in the fifth 
locus. All five loci contain genes that regulate immune functions and are plausible 
candidates for autoimmune disorders. SNPs in the PTPN22 locus are associated with 
RA, CD, SLE and T1D. The protein encoded by PTPN22 has been suggested to be 
involved in T cell, B cell and dendritic cell hyper-responsiveness and is a negative 
regulator of T cell activation (Zhang et al., 2011, Begovich et al., 2004). The 
TNFAIP3-OLIG3 locus is associated with psoriasis, RA, MS, SLE and possibly with 
CD. TNFAIP3 regulates TNF-mediated apoptosis and immune signaling, and its 
expression changes in response to the inflammatory cytokine TNFA. Little is known 
about human OLIG3, but the mouse ortholog is expressed in the developing neural 
tube (Takebayashi et al., 2002). The other members of this protein family, Olig1 and 
Olig 2, both promote oligodendrocyte differentiation in mice. The last locus contains 
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two genes ORMDL3, which negatively regulates sphingolipid synthesis, and IKZF3, 
a B lymphocyte development regulating transcription factor. This locus is associated 
with RA, CD, UC, T1D, and potentially with MS. TAGAP is associated with RA, 
MS, T1D, and UC, and it is thought to regulate T cell activation (Mao et al., 2004). 
REL is associated with psoriasis, RA, UC, and CD, and is thought to be involved in 
the development of regulatory T cells (Ruan et al., 2009). The TYK2 gene is 
associated with psoriasis, MS, SLE, and T1D (Table 3). Mutations in TYK2 can 
cause hyper immunoglobulin-E syndrome (HIES) and can potentially accelerate Th2 
development (Minegishi et al., 2006). Many of the associated genes have been 
suggested to be involved in common functions, such as Th17 cell development or 
function (e.g. STAT3, IL23R, IL7R, ETS1, CCR6, IL21) (Chaudhry et al., 2009, 
Langrish et al., 2005, McGeachy et al., 2009, Liu et al., 2010, Du et al., 2009, 
Yamazaki et al., 2008, Nurieva et al., 2007), macrophage (e.g. IL-23A, CD40) 
(Piskin et al., 2006, Becker et al., 2002) or B cell functions (eg. CD40) (Gerritse et 
al., 1996), dendritic cell functions (eg. MHC-II, IL23A) (Piskin et al., 2006), and in 
Treg cell functions (e.g. REL, STAT3, CCR6, IL2RA, CTLA4, IL10) (Ruan et al., 
2009, Chaudhry et al., 2009, Yamazaki et al., 2008, Asano et al., 1996, Fallarino et 
al., 2003, Asseman et al., 1999).  
Of the 192 autoimmune disorder associated genes, more than 130 genes associate 
only with one specific autoimmune disorder. These include, for example, the insulin 
gene in T1D, the gene encoding for matrix metalloprotease 27 in psoriasis, and the 
gene encoding for extracellular matrix protein 1 in UC. However, many of the 
distinctive loci have common roles in immunology, such as the T cell activating 
CD86 receptor in MS, and the T cell chemotactic CCL21 in RA. Due to the fact that 
all autoimmune diseases share currently 26-55% of their loci with at least one other 
autoimmune disease, and that the diseases have common features, it is likely that 
some of the genetic predisposition could be caused by common autoimmune 
susceptibility. On the other hand, at least half of the associated loci in each disease 
are unique to one disorder. Some of these loci may be found in other autoimmune 
disorders in the future, but a substantial part of the association signals seem to be 
distinct. Therefore it is unlikely, that the susceptibility to autoimmune disorders 
would be entirely a result of a common autoimmune susceptibility that is directed 
towards different epitopes. In MS, 36 of the 54 non-HLA loci are unique to the 
disease, whilst only 18 loci are associated with at least one other autoimmune 
disease (Mero et al., 2009, Patsopoulos et al., 2011, IMSGC, 2011).  
Many of the associated genes have known mutations that cause severe 
monogenic immunological disorders. For example, mutations in IL2RA can cause 
immunodeficiency (Sharfe et al., 1997) (OMIM #606367), mutations in IL7R cause 
severe combined immunodeficiency (SCID) (Puel et al., 1998), mutations in either 
STAT3 or TYK2 lead to hyper immunoglobulin-E syndrome (HIES) (OMIM 
#147060) (Minegishi et al., 2006, Minegishi et al., 2007, Holland et al., 2007), and 
mutations in TNFRSF1A cause familial Hibernian fever (OMIM# 142680) 
(Aksentijevich et al., 2001). One can hypothesize, that these genes could prove to be 
a good starting point for further functional studies also in complex autoimmune 
diseases. 
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Table 3. List of chromosomal positions and genes in or near loci that have been 
associated with at least three autoimmune diseases. 
Position Genes Disease Refrences 
6q23.3 TNFAIP3, 
OLIG3 
PS, RA, MS, 
SLE, CD 
Nair et al., 2009, Thomson et al., 2007, IMSGC, 2011, Graham et 
al., 2008, Franke et al., 2010 
1p13.2 PTPN22 RA, CD, SLE, 
T1D 
Begovich et al., 2004, Kyogoku et al., 2004, Gateva et al., 
2009, Barrett et al., 2008, Todd et al., 2007 
2p16.1 REL,  
PUS10 
PS, RA, UC, CD Strange et al., 2010, Gregersen et al., 2009, McGovern et al., 
2010, Festen et al., 2011 
6q25.3 TAGAP RA, MS, T1D, 
UC 
Raychaudhuri et al., 2009, IMSGC, 2011, Smyth et al., 2008, 
Festen et al., 2011 
17q12 ORMDL3, 
IKZF3 
RA, CD, UC, 
T1D 
Kurreeman et al., 2012, Barrett et al., 2008, McGovern et al., 
2010, Barrett et al., 2009b 
19p13.2 TYK2 PS, MS, SLE, 
T1D 
Strange et al., 2010, Mero et al., 2009, Sigurdsson et al., 
2005, Wallace et al. 2010 
1p31.3 IL23R PS, CD, UC Cargill et al., 2007, Duerr et al., 2006, Franke et al., 2008b 
1p36.32 MMEL1, 
TNFRSF14 
RA, MS, SLE Raychaudhuri et al., 2008, Ban et al., 2010, Kurreeman et al., 
2012 
1q32.1 IL10 UC, SLE, T1D Franke et al., 2008b, Gateva et al., 2009, Barrett et al., 
2009a 
1q32.1 KIF21B CD, UC, MS Barrett et al., 2008, McGovern et al., 2010, Barrett et al., 
2009b, IMSGC, 2011 
5q33.3 IL12B PS, CD, MS Cargill et al., 2007, Parkes et al., 2007, IMSGC, 2011 
6q21 PRDM1, 
ATG5 
CD, RA, SLE Barrett et al., 2008, Raychaudhuri et al., 2009, Gateva et al., 
2009 
10p15.1 IL2RA RA, MS, T1D Stahl et al., 2010, IMSGC, 2007, Vella et al., 2005 
17q21.2 STAT3 CD, UC, MS Barrett et al., 2008, Franke et al., 2008a, Jakkula et al., 2010 
18p11.2 PTPN2 RA, CD, T1D Okada et al., 2012, Parkes et al., 2007, Todd et al., 2007 
20q13.12 CD40 RA, MS, SLE Raychaudhuri et al., 2008, ANZgene, 2009, Vazgiourakis et 
al., 2011 
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3 AIMS OF THE STUDY 
The availability of comprehensive and affordable genome-wide methods, together 
with large international collaborative efforts, have increased the potential to identify 
new variants that are associated with complex phenotypes by increasing the sample 
size and power to detect loci with modest odds ratios. The overall objective of this 
thesis was to use SNP-based methods to identify, assess and compare genetic factors 
contributing towards MS predisposition in the Finnish and international populations. 
Our specific aims were: 
 
I To utilize the specific characteristics of the Southern Ostrobothnian 
case control cohort, such as an increased LD and a higher disease 
incidence, to identify new MS associated loci by using genome-wide 
SNP based, CNV and homozygozity analyses (Study I).  
 
II  To perform a replication meta-analysis study in 11 populations of 
European descent for three risk markers that were previously identified 
in an international genome-wide meta-analysis study (Study II). 
 
III  To investigate the role of common MS predisposing variants in the 
Finnish high-risk Southern Ostrobothnian isolate population, and in 
Finnish family samples (Study III).  
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4 MATERIALS AND METHODS 
4.1 Study cohorts 
4.1.1 Finnish study cohorts 
Finnish multiple sclerosis samples and anonymous population controls 
The Finnish multiple sclerosis study was approved by the Helsinki University 
Hospital ethics committee of ophthalmology, otorhinolaryngology, neurology and 
neurosurgery (approval 192/E9/02). Altogether 792 patient samples and 12 families 
with 139 additional family members were included in this study. The MS patients 
and their families were recruited from the University Hospitals of Helsinki, Kuopio, 
Oulu, and Tampere, and the Seinäjoki Central Hospital. The MS cases were 
diagnosed according to Poser criteria for clinically definite multiple sclerosis. All 
recruited individuals provided written informed consent. The 1,077 anonymous 
Finnish population controls were random visitors to either, the Seinäjoki Central 
Hospital, the University Hospital of Kuopio, or the University Hospital of Helsinki. 
71% of all available Finnish MS patients were female. Information on additional 
phenotypic parameters was available for 434 patients (Table 4). 9.3% of the patients 
had a diagnosis of PPMS, of which 46% were female. In the anonymous population 
sample 52% were female. 
Helsinki Birth Cohort Study cohort 
The Helsinki Birth Cohort Study (HBCS) sample is a part of the IDEFIX-study 
(Identifying Early Factors In Syndrome X); a cohort study of growth, cardiovascular 
diseases and living conditions, and psychological outcomes. The subjects were 
recruited based on their year and place of birth (Helsinki, Finland, 1934-1944). All 
participants gave written informed consent, and the study was approved by the 
Ethics Committee of Epidemiology and Public Health at Helsinki University 
Hospital and by the Helsinki and Uusimaa Hospital District (approvals 140/E3/2004, 
344/E3/2000 and 334/12/03/00/08). The sample set used in this study contained 
1,574 subjects after quality control. 
Table 4. Characteristics of the Finnish MS patients. 
 Mean Median Skew SD 
Age at onset (yrs) 30.36 30 0.422 8.59 
Duration (yrs) 14.16 13 0.773 9.08 
EDSS1 4.22 4 0.167 2.55 
1Expanded Disability Status Scale (Kurtzke, 1983) 
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The Cardiovascular Risk in Young Finns Study cohort 
The Cardiovascular Risk in Young Finns study is a cross-sectional follow-up cohort 
of Finns born between 1962 and 1977 (Raitakari et al., 2008). The subjects were 
recruited from Helsinki, Kuopio, Oulu, Tampere, and Turku (Raitakari et al., 2008). 
The cohort included in this study consisted of 2,333 individuals. The institutional 
ethics committees of the Universities of Helsinki, Kuopio, Oulu, Tampere, and 
Turku all approved the Young Finns study (Raitakari et al., 2008). Informed consent 
was obtained from all participants or from their guardians in the case of subjects 
under the age of 18 years (Raitakari et al., 2008). The Young Finns samples were 
included as controls in Study III.  
Health 2000 GenMets Study cohort 
The Health 2000 GenMets is a study of metabolic syndrome in the Finnish 
population (Perttila et al., 2009). The 2,194 subjects for the general Health 2000 
study were recruited from 80 regions across Finland. All participants gave their 
written consent and the Health 2000 study was approved by the Ethics Committees 
of the National Institute for Health and Welfare and the Ethics Committee for 
Research in Epidemiology and Public Health at the Hospital District of Helsinki and 
Uusimaa (Perttila et al., 2009). The GenMets study sample is a subset of Health 
2000, which were selected either as metabolic syndrome cases or matched controls 
(Perttila et al., 2009). We included a subset of 104 individuals from the GenMets 
study based on their place of birth and included as controls in Studies I and III.  
The Finnish Twin Cohort Study cohort 
The Finnish Twin Cohort Study is a longitudinal population-based sample set of 
twins. It has been collected for the study of genetic and environmental risk factors in 
chronic disorders. The twins were from across Finland and had been recruited using 
the Central Population Registry (Kaprio et al., 2002). A subset of 1,492 samples 
from the cohort, one twin per pair, was included as controls in Study III. The 
samples had been selected for a genome-wide study of either smoking or alcohol 
use. The study has been approved by the Ethics Committee of Epidemiology and 
Public Health at the University Helsinki Hospital and the Helsinki and Uusimaa 
Hospital District and the Institute Review Board of Indiana University. All 
participants provided informed consent. 
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4.1.2 International study cohorts 
Belgian cohort 
The Belgian study was approved by the Ethics committee of the University of 
Leuven (approval number ML4733). The Belgian cohort consisted of 776 patients 
that had been recruited through two centers: the National Multiple Sclerosis Center 
Melsbroek and the University Hospital Leuven (UZLeuven). All patients had MS 
either according to the Poser or the McDonald criteria (McDonald et al., 2001, Poser 
et al., 1983). In addition, the sample set included 1,021 unrelated controls from 
Belgium. All participants gave informed consent. The cohort was included in Study 
II. 
Danish cohort 
The Danish Research Ethics Committee approved the Danish study (approval KF 
01314 009). All participants gave informed consent. The 650 patient samples were 
recruited from The Danish MS Center in Copenhagen, Denmark and had multiple 
sclerosis according to the revised McDonald's criteria (Polman et al., 2005, 
McDonald et al., 2001). The Danish sample included 1,099 healthy Danish control 
samples. The cohort was included in Studies I and II. 
French trio cohort 
The French Ministry of Research approved the French MS study (approvals DC-
2008-539 and AC-2008-548). The cohort consisted of 608 trios, an affected child 
and their parents, recruited through a national media campaign. All patients fulfilled 
the Poser and revised McDonald criteria for MS (Poser et al., 1983, McDonald et al., 
2001, Polman et al., 2005, Goodkin et al., 1991). All participants gave informed 
consent. The cohort was included in Study II. 
German cohort 
The German study was approved by the Ethics committees of the Universities of 
Marburg, Düsseldorf, and Munich (approval 1856/07). The German cohort included 
930 patients with MS according to either Poser or McDonald criteria, and 911 
controls (Poser et al., 1983, McDonald et al., 2001). All study subjects gave their 
written informed consent. The cohort was included in Study II. 
Italian cohort 
The Comitato Etico (CE) Interaziendale in Novara, Italy, approved the Italian study 
(approval 570/CE, N. CE 38/0). The cohort included 629 patients with MS, 
according to the Poser criteria, and 828 regionally matched population controls. 
Informed consent was obtained from all patients (Poser et al., 1983). The cohort was 
included in Study II. 
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Norwegian cohort 
The Norwegian cohort consisted of 662 samples with MS, according to either the 
Poser or the McDonald criteria, and 1,027 healthy controls. The patients were 
recruited through neurological departments in Norway and the healthy individuals 
were randomly recruited through the Norwegian Bone Marrow Donor Registry. The 
study was accepted by the Ethics Committee South Eastern Norway (approval S-
08234a) and Local Data Inspectorate at Oslo University Hospital (2476). The cohort 
was included in Studies I and II. 
Cohorts from United States of America and United Kingdom 
The Partners Healthcare Institutional Review Board approved the USA and United 
Kingdom study (approval 2002-p-000434). The cohorts consisted of 656 MS cases 
and 714 controls from the UK, and 644 MS cases and 587 controls from the USA. 
The cases were diagnosed using McDonald criteria for multiple sclerosis (McDonald 
et al., 2001). All participants provided informed consent. The cohorts were included 
in Study II. 
Spanish cohort 
The cohort included 501 cases and 501 controls from Spain. All cases were 
diagnosed with clinically definite MS according to Poser's criteria. Control samples 
were anonymous samples from the Hospital Universitari Vall d´Hebron blood bank. 
All subjects gave written informed consent. The Spanish study was approved by the 
Ethics Committee of the Institut Català, Hospital Vall d’Hebron (approval 
PR(AG)30/2007). The cohort was included in Study II. 
Swedish cohort 
The Swedish samples were recruited from clinics all over Sweden. The cohort 
consisted of 2,016 patients with multiple sclerosis, according to either McDonald's 
or Poser’s criteria (McDonald et al., 2001, Poser et al., 1983), and 1,723 controls. All 
patients gave informed consent. The ethics committees of Regionala 
Etikprövningsnämnde, Stockholm, Sweden and Karolinska Institutets Regionala 
Forskningskomitté approved the study (approvals 04-252/1-4; 2006/845-31/1 and 
00-052, 04-375; 02-548). The cohort was included in Study II. 
Gene MSA cohorts  
The GeneMSA cohorts were from the United States of America (USA), Switzerland 
and the Netherlands (Baranzini et al., 2009b). The Dutch cohort consisted of 230 MS 
cases and 232 controls, the Swiss cohort of 253 cases and 208 controls and the USA 
cohort had 486 cases and 431 controls. The MS cases were recruited and collected at 
Vrije Universiteit Medical Center (Netherlands), University Hospital Basel 
(Switzerland), and University of California San Francisco (USA). All cases were 
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diagnosed using the new International Panel criteria for RRMS and the criteria for 
PPMS (McDonald et al., 2001, Polman et al., 2005, Baranzini et al., 2009). All 
participants gave informed consent prior to participation to the study and the studies 
were accepted by local Committees for Human Research. The cohorts were included 
in Studies I and II. 
Boston Women's Hospital cohort, USA  
The Boston Women's Hospital (BWH) cohort included 860 MS cases and 1,720 
controls (De Jager et al., 2009b). All patients, and part of the healthy controls 
(spouses and friends of MS patients), were recruited at the Partners MS Center in 
Boston, Massachusetts, USA. The remaining controls were from the MIGen study, 
and were either healthy individuals or had a history of early myocardial infarction 
(De Jager et al., 2009b). The cases were matched to two controls from a pool of 
2,951 subjects using EIGENSTRAT first principal component distance (De Jager et 
al., 2009b). All cases were diagnosed using the McDonald's criteria for MS (De 
Jager et al., 2009b). All individuals provided informed consent. This cohort was 
included in Studies I and II. 
International Multiple Sclerosis Genetics Consortium cohort  
The IMSGC study was reviewed by the Multi-Centre Research Ethics Committee 
(MREC) in the United Kingdom, and at the University of California Santa Fé and 
BWH Institutional Review Boards in the United States (IMSGC, 2007). All recruited 
individuals provided written informed consent. The MS cases from the United 
Kingdom were recruited from across the country, with the controls being the 2,950 
shared healthy controls from the Wellcome Trust Case Control Consortium 
(WTCCC) study (IMSGC, 2007, WTCCC, 2007). The cases from the United States 
were collected at multiple specialized clinical sites across the country, while the 
1,679 controls were healthy subjects from the National Institute of Mental Health 
cohort (IMSGC, 2007, De Jager et al., 2009b). The cases were diagnosed according 
to McDonald's criteria (Polman et al., 2005, McDonald et al., 2001, IMSGC, 2007). 
The cohort was included in Studies I and II. 
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4.2 Genotyping methods 
Genome-wide genotyping 
The Finnish samples were genotyped in two phases. First, 72 MS cases from 
Southern Ostrobothnia were genotyped using Illumina HumanHap310 gene chip 
(Illumina Inc., 5200 Research Place, San Diego, CA, 92122 USA) at the Broad 
Institute of MIT and Harvard’s Center for Genotyping (Cambridge, MA, USA). The 
Health 2000 GenMets sample was genotyped at DeCode Genetics (Reykjavik, 
Iceland) using the Illumina HumanHap610-quad chip (Illumina Inc., 5200 Research 
Place, San Diego, CA, 92122 USA) (Perttila et al., 2009). Only 297,343 SNPs that 
were common to both the Illumina HumanHap 310 and HumanHap610-quad 
platforms were kept for the analysis. Quality control was performed using PLINK. 
All SNPs with less than 95% of genotypes were excluded from the analysis. 
Individuals with <95% of genotypes, gender discrepancies or cryptic relatedness 
were excluded. Further, all SNPs with Hardy-Weinberg equilibrium test p<0.001 
were flagged as low quality markers for future analyses, but not removed. 
In the second genome-wide genotyping set, 651 cases and 139 additional family 
members from 12 families were genotyped using the Illumina HumaHap670 custom 
chip (Illumina Inc., 5200 Research Place, San Diego, CA, 92122 USA) at the 
Wellcome Trust Sanger Institute (Cambridge, UK). The Finnish population sample 
cohorts Young Finns and HBCS were genotyped at the same institute using the same 
genotyping chip. Eight samples from the families were re-genotyped using the 
Illumina HumanHap660W-quad chip (Illumina Inc., 5200 Research Place, San 
Diego, CA, 92122 USA) at the Technology Center of the Institute for Molecular 
Medicine FIMM (Helsinki, Finland). The genotypes were filtered using the 
following thresholds: MAF >1%, <5% missing genotypes, and Hardy-Weinberg p > 
10-6 in the Young Finns cohort. Individuals were excluded if they had >5% missing 
genotypes, excess or low heterozygosity compared to the rest of the strata, shared 
>20% by IBD with another sample, or showed cryptic relatedness. Samples with 
discrepancies between the reported and the observed gender were removed. 
The international sample sets BWH, IMSGC, and GeneMSA were genotyped at 
local institutes. The BWH was genotyped at the Broad Institute’s Center for 
Genotyping (Cambridge, MA, USA) using the Affymetrix Genechip 6.0 platform 
(Affymetrix Inc., 3420 Central Expressway, Santa Clara, CA 95951, USA)(De Jager 
et al., 2009b). The IMSGC sample sets were genotyped using the Affymetrix 
GeneChip Human Mapping 500K Array set (Affymetrix Inc., 3420 Central 
Expressway, Santa Clara, CA 95951, USA) at the Broad Institute of MIT and 
Harvard (Cambridge, CA, USA) and the controls were genotyped at the Affymetrix 
Services Lab (West Sacramento, CA, USA) (IMSGC, 2007, WTCCC, 2007). The 
GeneMSA sample sets were genotyped at the Illumina facilities using Sentix® 
HumanHap550 BeadChip (Illumina Inc., 5200 Research Place, San Diego, CA, 
92122 USA) (Baranzini et al., 2009). These international sample sets were imputed 
by De Jager et al. 2009 using MACH version 1.0.5 and phased using the Utah 
residents with ancestry from northern and western Europe (CEU) population in 
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HapMap release 21 as a reference (De Jager et al., 2009b). The imputed genotypes 
were filtered using standard quality metrics: SNPs with <5% missing genotypes, 
>1% MAF, and Hardy-Weinberg p> 10-6 were included (De Jager et al., 2009b). 
Sequenom® genotyping in Studies I and II 
Sequenom® iPLEX and iPLEX Gold MassARRAY® systems were used to genotype 
the samples for Studies I and II. The primers were designed using the MassARRAY® 
AssayDesigner (Sequenom®, 3595 John Hopkins Court, San Diego, CA 92121-
1331). The default settings were used, except for the following modification: mass 
range from 4,300 to 8,500, and a maximum iPLEX size of 40 SNPs. The primers 
were ordered from Metabion (Metabion GmbH, Lena-Christ-strasse 44, 82152 
Martinsried, Germany). The iPLEX and iPLEX Gold protocol provided by the 
manufacturer (Sequenom®, 3595 John Hopkins Court, San Diego, CA 92121-1331) 
was used for genotyping. The reagents were purchased from Sequenom 
(Sequenom®, 3595 John Hopkins Court, San Diego, CA 92121-1331). Genotypes 
were inspected visually using MassARRAY® Analyzer. All samples with <50% of 
genotypes per iPLEX were excluded. All markers with water contamination, <90% 
success rate, or discrepant duplicate results were excluded. The genotyping was 
performed in the Institute for Molecular Medicine Finland (FIMM) Technology 
Centre. In Study II the genotyping was performed in the participating laboratories, 
except for the Danish and Norwegian cohorts that were genotyped in the Institute for 
Molecular Medicine (FIMM) together with the Finnish cohort. All genotypes were 
combined to a single file, together with the TaqMan genotypes for the quality control 
and analysis steps. 
Taqman genotyping in Study II 
The SNP rs1800693 was genotyped using the c__2645714_10 TaqMan® assay (Life 
Technologies Corporation, 5791 Van Allen Way, Carlsbad, CA 92008, USA) and 
the TaqMan® end point genotyping protocol by Applied Biosystems (Life 
Technologies Corporation, 5791 Van Allen Way, Carlsbad, CA 92008, USA). The 
PCR was optimized to 35 cycles and the annealing temperature was set to 63ºC. An 
ABI 7900HT instrument was used for genotyping, and to visually analyze the 
genotype clustering. The genotyping was performed in the individual participating 
laboratories using either TaqMan or Sequenom genotyping, except for the Danish 
and Norwegian cohorts, that were genotyped together with the Finnish cohort in the 
Institute for Molecular Medicine Finland (FIMM). All genotypes were combined to 
a single file for the quality control and analysis steps. 
Copy-number variation genotyping in Study I 
The QuantiSNP program was used to genotype CNVs in the Study I sample sets 
using the defaults for the following: GC correction, Bayesian factor > 10 and length 
≥ 3 SNPs. All genotype calls were verified visually using Bead Studio 3.3 (Illumina 
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Inc., 5200 Research Place, San Diego, CA, 92122 USA) with CNVs in the 
centromeric regions being excluded. CNVs that had undergone replications were 
genotyped using either a multiplex fragment PCR (CNVs near the DLG2 and NRG3 
genes), or a single fragment PCR (CNV near the ERBB4 gene). PCR reactions were 
performed in a 10μl reaction volume with final concentrations of 1x GeneAmp® 
PCR Gold buffer (Life Technologies, Carlsbad, California, USA), 1.50 mM MgCl2 
(Qiagen N.V., Spoorstraat 50, 5911 KJ Venlo, Netherlands), 200μM dNTPs, 0.55U 
AmpliTaq Gold® DNA ploymerase (Life Technologies, Carlsbad, California, USA), 
300 nM of each forward primer, and 200nM of the labeled reverse primer. Primer 
sequences were ordered from Sigma-Aldrich (Sigma-Aldrich, 3050 Spruce Street, 
St. Louis, Missouri 63103, USA): 
DLG2, labeled forward primer FAM-CAACTGCAATTTCCTTCTGGA,  
DLG2, reverse primer 1  AGAGTAGAGGCAAGGCAGCA,  
DLG2, reverse primer 2  TTTGAAGGGCAGTTTGCAC,  
ERBB4, labeled forward primer VIC-GTAAGTCTTGCCCGAAGCTG,  
ERBB4, reverse primer 1  GGAGGTGGGTGTATTTGTTCC,  
ERBB4, reverse primer 2 (deletion) TGTGAGAACAGGCCTTGGA, 
NRG3, labeled forward primer NED-GGGGAAATGATTGTGGTTCA,  
NRG3, reverse primer 1 (deletion) AAATGCCTGGATCAAACCAA, 
NRG3, reverse primer 2  AGGGGTGTGGAGGATATAGGA.  
The PCR program included an initial denaturation step (12 minutes, 94?C), 30 
cycles of amplification (30 s in 94?C, 15s in 61?C, 45 s in 72?C), and a final 
extension step (10minutes in 72?C). The PCR products were diluted in Hi-DiTM 
Formamide (Life Technologies, Carlsbad, California, USA) and run on the Applied 
Biosystems ABI 3730xl DNA Analyzer (Life Technologies, Carlsbad, California, 
USA) with the GeneScanTM -500 LIZ® standard (Life Technologies, Carlsbad, 
California, USA). The alleles were called using the GeneMapper 4.0 software (Life 
Technologies, Carlsbad, California, USA). The CNV genotyping was performed at 
the Institute for Molecular Medicine Finland FIMM Technology center. 
4.3 Statistical methods 
4.3.1 Study I: Genome-wide association study in a Southern 
Ostrobothian isolate 
In order to control for cryptic relatedness in the 72 Southern Ostrobothnian cases and 
2,194 GenMets samples, identity-by-descent (IBD) analysis was performed using 
PLINK (Purcell et al., 2007). First, a pruned genotype set was obtained using the 
PLINK nearest neighbor clustering method (pair wise population concordance = 
0.05). Next, a multidimensional scaling (MDS) analysis was used to assess the 
clustering, or potential discrepancies in reported ancestry (Figure 6). The MDS 
analysis was used to collapse the IBD matrix data (Purcell et al., 2007). MDS results 
for the first and second dimension were plotted using Microsoft MS Office Excel. 
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Figure 6 Multi-dimensional scaling MDS plot. The first two dimensions from the MDS 
analysis of the 72 cases and 2,194 population samples from the GWA study are shown. The 
MS samples that were included in the analysis are marked with red dots and the IBD 
selected controls are marked with blue dots. MS cases and population samples that were 
excluded based on this analysis are marked with yellow and grey dots, respectively. 
The distances between cases and controls in the first two dimensions are presented in 
Figure 3. Outlying cases were removed based on a visual inspection of the graph. 
The IBD matrix was then used to select the two closest controls for each case, by 
using the clustering option in PLINK. After quality control (QC) and clustering, 68 
of the 72 cases and 136 controls from the GenMets sample set remained in the 
analysis. The genomic inflation factor for the IBS matched sample set was 1.08 
compared to the 1.57 for the non-matched sample set.  
First, the sample set was analyzed for long homozygous stretches in the genome, 
in order to find potential large shared recessive risk haplotypes by using PLINK 
(Purcell et al., 2007). The minimum length was set to at least 50 consecutive SNPs 
and 500 kb per individual, per locus. The samples were then inspected for 
overlapping homozygous segments. The most promising overlapping homozygous 
segments were analyzed for statistical significance using permutation. The case-
control labels were permuted 10,000 times to obtain an empirical p-value, to correct 
for the number of independent tests in the ROH analysis. As the PLINK software 
does not analyze the haplotypes within the homozygous regions. Therefore, the 
overlapping homozygous regions with an empirical p< 10-3 were assessed for 
haplotype consistency. 
Next, standard association test and association tests with dominant, recessive, 
and additive models were used to identify the most interesting loci with a p < 10-4. 
These loci were then validated in a Finnish replication set of 83 cases and 365 
controls from Southern Ostrobothnia, and 628 cases and 668 controls from 
elsewhere in Finland. These samples were analyzed as separate clusters using a 
Cochran-Mantel-Haensel (CMH) meta-analysis, in order to control for population  
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stratification. The two loci that passed the threshold of p<0.05 were analyzed in the 
international sample sets described in Table 5. The analysis was performed using 
CMH analysis and treating each sample set and nationality as a separate cluster. The 
STAT3 locus haplotype structure was analyzed, to assess the haplotype background 
of the associated variant. The haploblock length and its constituent haplotypes were 
estimated using Haploview 4.0 in HapMap populations (Barrett et al., 2005). The 
information of the CEU population in HapMap release 23a was used to estimate the 
haplotype block structure using the Gabriel method (Barrett et al., 2005, Gabriel et 
al., 2002). The same haplotype was estimated in the YRI and CHB populations, as 
well. Three tagging SNPs from the rs744166 containing haplotype block were 
selected for haplotype analysis using the default parameters for pair-wise tagging in 
Haploview 4.0 and they were verified visually from the CEU haplotypes (Barrett et 
al., 2005). Haplotypes were estimated for all individuals from data sets with 
available SNP genotypes using PLINK. The CMH meta-analysis of the haplotypes 
was conducted, and each population was treated as a separate cluster so as to control 
for population stratification. 
Since no systematic studies of CNVs in MS have been reported, our aim was to 
identify CNVs that could affect MS predisposition. The CNVs were genotyped using 
the intensity data from the microarray and the QuantiSNP program. Those CNVs 
that were observed in the 68 MS cases were analyzed using the Ingenuity® Pathway 
Analysis. The UCSF Genome Browser March 2006 release (NCBI36/hg18) was 
used to search for genes within the CNVs. All genes were analyzed for interactions 
and common functions with the Ingenuity Pathway Analysis software (Ingenuity® 




Table 5. List of international replication sample sets included in the genome wide 
association study in Study I. 
Country of origin Sample set Number of MS cases Number of controls 
Norway NO 607 816 
Denmark DK 628 1074 
Netherlands GeneMSA NL 230 232 
Switzerland GeneMSA CH 253 208 
United States GeneMSA US 486 431 
United Kingdom IMSGC UK 453 2950 
United States IMSGC US 342 1679 
United States BWH 860 1720 
Total  3859 9110 
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4.3.2 Study II: Meta-analysis of international replication cohorts  
The meta-analysis method by Kazeem and Farrall, for a combined analysis of trios 
and case-control data, was used in study II (Kazeem and Farrall, 2005). We analyzed 
the cohorts presented in Table 6 as separate clusters, to control for differences in 
population structures. Additionally, the Finnish sample sets were split into two 
clusters to separate out the Southern Ostrobothnia isolate from other Finnish 
samples, resulting in a total of 12 clusters. Analysis was performed in R 2.9.0 by 
using the formulas provided in the meta-analysis article by Kazeem and Farrall 2005. 
The method weights each cluster taking into account both the sample size and the 
effect size. 
4.3.3 Study III: Genetic burden analysis in families and in the 
Southern Ostrobothnian isolate 
We used a genetic burden analysis based on a previously published weighted log-
additive score (De Jager et al., 2009a, Gourraud et al.). We adapted the score to 
include 50 non-HLA SNPs that have been previously reported to associate with MS, 
at a genome-wide significant level, and the HLA-DRB1*1501 allele tagging the SNP 
rs9271366 (de Bakker et al., 2006, IMSGC, IMSGC, 2007). In the CEU HapMap 
population (release 27), the SNP rs9271366 is in full LD (r2 1, D’ 1) with rs3135388, 
which in turn is in high LD (r2 0.966, D’ 0.993) with the HLA-DRB1*1501 allele (de 
Bakker et al., 2006, IMSGC, 2007). We used the SNPs, risk alleles, and ORs 
reported in the IMSGC 2011 paper to calculate the genetic burden score, since it 
covered all of the genome-wide significant loci up to that date and were genotyped 
using the same platform as our cohort (IMSGC). For the rs9271366 SNP we used the 
OR reported for rs3135388 (OR 1.99) in the first multiple sclerosis GWAS that used 
trio samples (IMSGC, 2007). 
 
Table 6. List of cohorts in the meta-analysis in Study II. 
Sample set Number of trios Number of MS cases Number of controls 
Belgium (BE) - 776 1021 
Denmark (DK) - 634 1090 
Finland (FI) - 792 1077 
France (FR) 608 0 0 
Germany (DE) - 930 911 
Italy (IT) - 828 629 
Norway (NO) - 662 1027 
Spain (ES) - 501 501 
Sweden (SE) - 2016 1723 
United Kingdom (UK) - 656 714 
United States (US) - 644 587 
Total  608 8439 9280 
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Genetic burden scores were calculated to each sample individually. R 2.15.1 was 
used to analyze the genetic burden score data (R Core Team, 2012). The distribution 
of the genetic burden scores were both drawn as histograms, and evaluated using the 
Shapiro-Wilkins test for normality. Although the distributions appeared normal, or 
did not differ significantly from normal distribution in the Shapiro–Wilkins test, 
statistical differences between sample groups were assessed using the non-
parametric Kolmogorov-Smirnov test. Interactions between the affection status and 
region of origin against the genetic burden score were calculated using both an 
additive and a multiplicative regression models.  
DSS Researcher's toolkit power and sample size analyses were used to estimate 
power together with simulations in R 1.15.1. The observed number of samples, 
genetic burden score averages, and standard deviations in each sample group were 
used when possible. The familial cases and Southern Ostrobothnian samples were 
kept at the observed constant and the values for the other group were altered 
according to simulation or calculation. The simulations for the power in the familial 
samples versus sporadic samples were calculated assuming normal distribution. For 
group one, the values were as follows: number of samples 63, average 6.8 and 
standard deviation 0.64. For group 2 the input values were as follows: number of 
samples 522, standard deviation 0.62 and average was either 6.6 or 6.53, depending 
on the assumed difference between the populations in the simulation. There were 
1,000 to 10,000 simulation rounds during which random values were drawn from 
two normal distributions. Each rounds averages, KS-test, Welch t-test, and the 
average1-average2 difference were calculated and those values were stored in a 
table, and the stored values were observed to estimate the power and chance of a 
false negative finding. 
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5 RESULTS AND DISCUSSION 
5.1 Association between variants in STAT3 and MS, 
Study I 
Genetic variants can be enriched in isolate populations and can cause unusually high 
prevalence of a phenotype. Such a phenomenon is profound for monogenic 
phenotypes, such as the diseases of the Finnish disease heritage. It has been 
hypothesized that a similar phenomenon could be involved in complex diseases, 
although the effect of genetics on disease predisposition is complex. The Southern 
Ostrobothnian population history supports the prospect of a founder effect in the 
region, and there is also a two-fold increase in prevalence and incidence of MS in the 
area (Sumelahti et al., 2000, Sumelahti et al., 2001, Tienari et al., 2004). Therefore, 
it is reasonable to hypothesize that MS predisposing variants could exist in this 
isolated region.  
The 72 MS cases from Southern Ostrobothnia, and the 2,194 population samples 
from the GenMets cohort were initially included in our GWAS analysis. All samples 
were analyzed for IBD sharing, with no excess sharing being observed. 
Multidimensional scaling (MDS) analysis revealed that the Southern Ostrobothnian 
samples formed a distinct cluster from the other Finnish samples (Figure 3), which 
supports the isolate nature of the region. The first two clustering dimensions were 
then used to estimate the origin of individual samples, and 4 of the 72 cases were 
excluded from the initial isolate sample (Figure 3) (Jakkula et al., 2008). In total, 68 
cases were included in the final analyses. Next, PLINK genome-wide clustering 
options were used to select the two closest controls for the remaining cases, 136 
controls in total, from the available pool of 2,194 population selected samples 
(Purcell et al., 2007). The places of birth were then verified for the IBD matched 
controls with all samples originating from Southern Ostrobothnia. 
Association between STAT3 SNP rs744166 and MS in Finnish samples 
Association analyses were performed using PLINK. The genomic inflation factor 
was found to be reasonable with λ = 1.078. The HLA-locus was the only locus that 
reached a genome-wide significant association (p=1.35×10-10 for rs3135338) (Figure 
7). In total, 37 SNPs in 27 loci displayed at least modest association with MS 
(uncorrected p < 10-4). A minimum of one SNP per locus was included in the first 
follow up step. A total of 28 SNPs were genotyped in an independent Finnish sample 
set of 83 cases and 365 controls from Southern Ostrobothnia, and 628 cases and 664 
controls from elsewhere in Finland. Of the 27 loci, three displayed modest 
association with MS: rs3135338 in the HLA-region (p=1.6×10-25, OR=3.43), 
rs744166 in the first intron of the signal transducer and activator of transcription 3 
(STAT3) gene on chromosome 17q21.2 (p=0.0012, OR=1.27), and rs1364194 on  
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Figure 7 Manhattan plot of the GWA results. The loci that passed the first replication step are 
indicated in the figure: the HLA locus on chr 6p (including rs3135338), the rs1364194 on chr 
16q and the rs744166 in the STAT3 gene on chr 17q. The other regions were excluded, 
since the results could not be replicated in the Finnish sample set. 
chromosome 16q21 (p=0.0047, OR=1.48). The closest genes to rs1364194 were 1 
Mb away. 
Next, we aimed to assess the significance of the two promising initial results, the 
associations between rs744166 and rs1364194 and MS, in a large international set of 
independent samples. The well known HLA locus was excluded from the analysis. 
Altogether, 3,859 MS cases and 9,110 controls from six populations and eight 
sample sets were analyzed using CMH meta-analysis (see Material and methods, 
section 4.3.1, Table 5).  The genotypes for the two SNPs had been imputed in the 
IMSGC data sets, but directly genotyped in the other sets. No significant 
heterogeneity of odds ratios was observed, using the Breslow-Day test for 
heterogeneity, and the CMH analysis of all independent replication and validation 
sets confirmed the association with rs744166 in the STAT3 gene (p=2.75×10-10, 
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The associated SNP rs3135338 is located in the HLA-II DRB1-locus and is in modest 
LD with SNP rs3135388 (r2=0.51, D’=1.0) in the CEU population (HapMap release 
27) (International HapMap Consortium, 2003). The rs3135388 SNP is, additionally, 
in tight LD with the HLA-DRB1*1501 allele (r2=0.966, D’=0.993) (de Bakker et al., 
2006), which has been consistently linked and associated with MS (Olerup and 
Hillert, 1991, Sawcer et al., 1996, Tienari et al., 1993, IMSGC, 2007, Jersild et al., 
1972, Patsopoulos et al., 2011, Jakkula et al., 2010, IMSGC, 2011, ANZgene, 2009). 
The HLA region has strong LD and a complex structure (de Bakker et al., 2006, 
Horton et al., 2008) and only recent well-powered studies have been able to refine 
association signals in the region (IMSGC, 2011). Today, at least four different HLA-
alleles have been associated with MS: HLA-DRB1*1501, HLA-DRB1*0301, HLA-
A*0201 and HLA-DRB1*1303 (IMSGC, 2011, Fogdell-Hahn et al., 2000, Harbo et 
al., 2004). Some of the alleles are in strong LD with other loci in the HLA region, 
and therefore, their effects cannot be separated at this stage (IMSGC, 2011). 
The SNP rs2293152 in the STAT3 gene, was suggestively associated with MS in 
a previously published meta-analysis, but the association was not replicated (De 
Jager et al., 2009b). The same group recently extended their previous meta-analysis, 
and reported that rs2293152 is indeed associated with MS (Patsopoulos et al., 2011). 
However, the cohorts in the meta-analyses significantly overlapped with each other 
and with those of our study (De Jager et al., 2009b, Jakkula et al., 2010, Patsopoulos 
et al., 2011). The Gene MSA, IMSGC and parts of the BWH cohort are included in 
all three studies, and further, all the samples from the first meta-analysis were 
included in the follow up step of our study (Patsopoulos et al., 2011, De Jager et al., 
2009b, Jakkula et al., 2010). The associated SNP in the meta-analyses is only in 
moderate LD (r2=0.352, D’=0.861) with rs744166 in the CEU population (HapMap 
release 27) (International HapMap Consortium, 2005). 
A Spanish study with 1,540 cases and 1,720 controls did not find evidence for 
association between rs744166 in STAT3 and MS (Cenit et al., 2010). However, two 
more recent studies detected an association with MS at the STAT3 locus (IMSGC, 
2011, Lill et al., 2012). An independent German study reported a weak association 
with rs744166 (p=0.012, OR=1.09) in a reasonably large German cohort with 2,932 
MS cases and 2,972 controls (Lill et al., 2012). Additionally, an international GWAS 
reported a strong association with rs9891119 (p=1.80×10-10, OR=1.11), which is in 
LD with rs744166 (r2=0.65, D’=1.0) in the CEU population (HapMap release 27) 
(IMSGC, 2011). It should be noted, that the international GWAS is not completely 
independent of the current study (IMSGC, 2011). At least some of the samples are 
overlapping with the Finnish, Norwegian and Danish sample sets, however, the 
overlapping cohorts represent a minority of the total samples analyzed (maximum of 
1,520 of 9,772 cases and 121 of 16,849 controls overlap) (IMSGC, 2011). The 
associated SNP rs9891119 resides in the same LD block as rs744166 and is in LD 
with it (r2=0.69, D’=1.0) in the CEU population (HapMap release 27). It is therefore 
possible, that both association signals may point towards the same effective variant 
or variants. 
The association between rs1364194 on chromosome 16 and MS was not 
replicated in the international replication meta-analysis. The chromosome 16 SNP 
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could represent a false positive initial finding, and is unlikely to be relevant in MS 
predisposition in general. However, we cannot exclude the option, that it might be 
relevant in the Southern Ostrobothnian isolate population. Due to lack of plausible 
candidate genes or functional elements, we cannot speculate its potential function or 
functional relevance. 
5.1.1 Association between common haplotypes in STAT3 and MS 
We analyzed the haplotype structure around rs744166 in the HapMap 2 populations 
(release 23a) using Haploview (Barrett et al., 2005, International HapMap 
Consortium, 2003). Using the Gabriel et al. block definition method, the rs744166 
was found to reside in a LD-block that covers the beginning of STAT3 from the 
immediate promoter region to exon 4 (Barrett et al., 2005). In the CEU population 
the haplotype block is 40 kb long and, using the HapMap 2 release SNP resolution, 
five different haplotype backgrounds for the block could be defined. The rs744166 
A-allele was present on only one haplotype in the Utah residents with ancestry from 
Northern and Western Europe, USA, (CEU), the Japanese from Tokyo, Japan, (JPT), 
and the Han Chinese from Beijing, China, (CHB) HapMap populations, but on four 
different haplotypes in the Yoruba from Ibadan, Nigeria, (YRI) population. 
We used the Haploview haplotype tagger to select three additional SNPs to cover 
all of the variation in the CEU population. One SNP failed in both genotyping and 
the QC phase, leaving a total of three SNPs, including rs744166, for the haplotype 
analysis. In addition to the Finnish samples, the genotypes for the three SNPs were 
available in six other cohorts, (from the US, the UK, Netherlands, and Switzerland). 
In total, 3,377 MS cased and 8,295 controls were included in the haplotype analysis 
using PLINK. Association analysis was performed for each sample set, and the 
combined data set using CMH meta-analysis (Purcell et al., 2007). The two most 
common haplotypes were associated with MS (Table 7). The analysis could not 
discern if there was an associated and a reciprocal haplotype, or if both haplotypes 
were truly associated with MS. Interestingly, the protective A-allele that tags the 
protective haplotype in populations outside of Africa was common in the CEU 
population (frequency 0.56), the CHB population (frequency 0.65), and the JPT 
population (frequency 0.57), whilst it was rarer in the YRI population (frequency 
0.25) (HapMap release 27). The haplotype distributions were similar in all studied 
populations, including Southern Ostrobothnia and elsewhere in Finland. 
Pickrell et al. searched for regions under selection in the human genome. The 
SNP rs744166 was among the analyzed SNPs and its allele distribution varied 
throughout the worlds populations (Pickrell et al., 2009). However, rs744166 did not 
show significant evidence for positive selection in the study by Pickrell et al., 2009, 
although its frequency has increased in the populations outside of Africa (Pickrell et 
al., 2009).  
The STAT3, STAT5A and STAT5B genes each encode transcription factors of the 
STAT-family, whose members are involved in the immune system functions, and  
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Table 7. The two most common haplotypes and their frequencies in the STAT3 locus 
were associated with MS in the haplotype analysis of 3,377 cases and 8,295 controls from 
five populations.  
Haplotype by SNP alleles of 






CGG 0.308 0.276 1.17 7.51×10-7 
TAA 0.549 0.582 0.87 4.26×10-6 
TGG 0.086 0.081 1.07 0.181 
CGA 0.057 0.061 0.93 0.169 
 
regulation of cell growth and apoptosis (Yao et al., 2006, Imataki et al., 2012, 
McLoughlin et al., 2005, Li et al., 2012b, Friedrichsen et al., 2001, Tronche et al., 
2004). The STAT3 protein is phosphorylated and thus activated in response to 
cytokines or growth factors, for example IL-6 (Li et al., 2012b, McLoughlin et al., 
2005). The activated STATs form homo- or heterodimers with other STAT-family 
members and are transported to the nucleus where they activate transcription 
(McLoughlin et al., 2005, Yuan et al., 2005, Wang et al., 1996). 
STAT3 is thought to be involved in the regulation of apoptosis (Li et al., 2012b), 
supporting CD8+ dependent T cell activation (Imataki et al., 2012), fetal astrocyte 
development (Nakashima et al., 1999), Treg cell regulatory functions (Chaudhry et 
al., 2009), and as a key factor in Th17 cell differentiation (Liu et al., 2010). There is 
increasing evidence for the importance of Th17 cells in MS (Du et al., 2009, Kebir et 
al., 2007), in rodent EAE (Du et al., 2009, Cua et al., 2003), and in other 
autoimmune diseases (Nakae et al., 2003, Murphy et al., 2003). Mutations in STAT3 
have been reported to cause hyperimmunoglobulin E recurrent infection syndrome 
(HIES), also known as Job’s disease (Holland et al., 2007, Minegishi et al., 2007). 
HIES is a monogenic autosomal dominant immune disorder characterized by 
inflammation and elevated immunoglobulin E levels (Holland et al., 2007, Minegishi 
et al., 2007).  
The rs744166 in STAT3 has also been associated with CD (Barrett et al., 2008). 
Interestingly, the MS risk increasing rs744166 C-allele (C) from our study was 
indicated to be the protective allele in CD (Barrett et al., 2008). In addition to the 
genetic associations, some functional evidence suggests that STAT3 is involved in 
other autoimmune diseases, such as psoriasis (Sano et al., 2005) and CD (Lovato et 
al., 2003). The STAT3 pathway has been reported to be involved in the regulation of 
neuroinflammation and autoimmune demyelination in mice, possibly through Th17 
cells (Mycko et al., 2012, Qin et al., 2012). 
Further, rs744166 has been reported to be a tissue specific eQTL that regulates 
the expression of the adjacent Signal transducer and activator if transcription 5A and 
5B (STAT5A and STAT5B) genes in a tissue specific manner (Dimas et al., 2009). 
Therefore, it is possible that the effect of the STAT3 MS locus could be mediated 
through the STAT5A and STAT5B genes. Knock-out studies in mice have shown that 
Stat5A and Stat5B are required for the development of hematopoietic cell lines 
during fetal development (Snow et al., 2003, Socolovsky et al., 1999, Yao et al., 
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2006). Knock-down and knock-out studies of the Stat5A and B genes in mice have 
been reported to cause fetal anemia, autoimmunity, decreased lifespan, perinatal 
lethality and a potential severe combined immunodeficiency (SCID) -type phenotype 
(Snow et al., 2003, Socolovsky et al., 1999, Yao et al., 2006). Interestingly, STAT5 
has been suggested to be required for the survival and expansion of Th17 cells in 
response to activation on the IL7-IL7R signaling pathway (Liu et al., 2010). 
5.1.2 Three regions of homozygosity in MS 
Extended regions of homozygosity (ROHs) were analyzed in the Finnish GWAS 
sample set of 68 cases and 136 controls to find potential recessive loci. The 
minimum length for an individual ROH in an individual sample was set to 500kb to 
find large ROHs that could have been inherited from a common ancestor, and each 
ROH was required to cover at least 50 consecutive SNPs. All Finnish GWAS 
samples were compared to one another to identify potential overlap between the 
individual ROHs. On average, each sample had 149 ROHs (standard deviation 12 in 
cases, 10 in controls) that were 1030kb long (range 0.5-31.3Mb) in cases, and 
1018kb (range 0.5-49.6Mb) in controls. All overlapping regions were permuted 
10,000 times to find an empirical p-value for the enrichment of ROH in cases 
compared to controls. 
Three regions of interest emerged (empirical p < 10-3): 1q42.12 (242kb, 
p=0.0003), 2q24.3 (512kb, p=0.00008) and 12q24.33 (573kb, p=0.0003). In 1q42.12 
and 2q24.3, a single haplotype was more frequent in the MS cases compared to 
controls (13% vs. 9% and 37% vs. 20%, respectively). The Health 2000 GenMets 
population samples were similar to the isolate controls: haplotype frequency in the 
1q42.12 was 6% and haplotype frequency in the 2q24.3 was 20%. This indicates that 
these haplotypes could be enriched in the MS cases, at least in the isolate region. The 
third locus, in 12q24.33, had multiple associated haplotypes, and no single haplotype 
stood out. The 12q24.33 locus has been suggestively linked to MS in a previous 
study (Haines et al., 2002), but no strong evidence for association or linkage has 
been found for any of the loci (Patsopoulos et al., 2011, IMSGC, 2011). The 1q42.12 
locus includes an open reading frame, and the 5’ end of DISP1 gene that is involved 
in embryonic development. The 2q24.3 locus includes the 3’ end of the XIRP2 gene 
that is involved in actin filaments. There are several genes in the 12q24.33 locus: 
SFRS8, MMP17, ULK1, PUS1, EP400, EP400NL, DDX51, NOC4L, and GALNT9. 
These genes are involved in RNA processing, extracellular matrix, autophagy, and 
nuclear membrane. None of these genes are obvious candidate genes for MS. Further 




5.1.3 Copy-number variants in MS patients 
The Illumina HumanHap 300 platform is sparse, and most common CNV regions 
have been excluded from the chip. Therefore, our aim was to identify potential rare 
CNVs enriched in the Southern Ostrobothnian isolate region. CNV analysis of the 68 
patients revealed 106 CNV regions. Nine of the 106 CNVs were previously 
unidentified, and each one was only observed once.  
We hypothesized that the genes within, or next to, the CNVs could be a part of a 
common pathway that might play a role in MS etiology. Ingenuity Pathway Analysis 
revealed a single pathway, potentially regulating oligodendrocyte differentiation and 
myelin sheet formation, that involved the genes neuregulin 3 (NRG3), v-erb-a 
erythroblastic leukemia viral oncogene homolog 4 (ERBB4), discs, large homolog 2 
(DLG2), utrophin (UTRN), and like-glycosyltransferase (LARGE). The CNVs in 
question were genotyped in a set of 703 MS cases and 1051 controls using a 
fragment analysis method. However, the CNV frequencies were not significantly 
different between the cases and controls. Eleven per cent of the MS cases carried a 
deletion in the ERBB4 gene compared to 12% of controls (p=0.388), and the deletion 
in NRG3 was present in 4% both in of cases and controls (p=0.90). The deletion in 
DLG2 was present in 1% of cases, but was not detected at all in controls, and thus, 
needs to be further studied in order to define its significance. We were unable to 
define the borders for one deletion and one duplication, which lead to their 
exclusion. Based on this analysis, we could not identify any large rare CNVs that 
were enriched in the MS patients. 
5.2 Meta-analysis of association between rs1800693 
(TNFRSF1A), rs17445836 (IRF8) and rs17824933 
(CD6) and MS, Study II 
A recent meta-analysis of five independent data sets identified three genome-wide 
significant SNPs: rs1800693 in the tumor necrosis factor receptor superfamily, 
member 1A gene (TNFRSF1A), rs17445836 that is located 61.5 kb from the 
interferon regulatory factor 8 gene (IRF8) also know as interferon consensus 
sequence-binding protein gene (ICSBP), and rs17824933 in CD6 (De Jager et al., 
2009b). Our aim was to confirm the association of these loci with MS in another 
large international sample set. The study set included 8,047 cases, 9,174 controls and 
608 trios from 11 populations across Europe and the USA (Materials and methods 
4.3.2, Table 6). If a sample set didn’t meet the quality control criteria for one of the 
SNPs, the sample set was excluded from the analysis of that particular SNP. We 
excluded the Danish and French samples from the analysis of TNFRSF1A, and the 
Spanish and German samples from the analysis of IRF8. 
The data was analyzed using a meta-analysis method by Kazeem and Farrall 
2005 that allowed us to include both case-control data and trios into the same 
analysis (Kazeem and Farrall, 2005). The strongest association with MS was 
observed at the IRF8 locus (p=5.34×10-10, OR=0.84, 95% CI 0.80-0.89). The 
associations at the TNFRSF1A and CD6 loci were more moderate (p=4.19×10-7, 
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OR=1.12, 95% CI 1.07-1.18 and p=2.19×10-5, OR=1.11, 95% CI 1.06-1.11, 
respectively). Combining these results with the results from the original publication 
strengthened the association results: TNFRSF1A p=8.12×10-12 (OR 1.15), IRF8 
p=3.35×10-15 (OR=0.83), and CD6 p=8.88×10-12 (OR=1.16). The results for CD6 
were the least significant, and the OR varied between populations. These loci have 
been further confirmed in recent studies (IMSGC, 2011).  
The IRF8 gene encodes a transcription factor that binds to the interferon-
stimulated response element (ISRE) in response to the type I interferons (e.g 
interferon-α), (Weisz et al., 1992, Nelson et al., 1993). This protein has been 
reported to be important in the regulation of macrophage development, B cell 
differentiation (Tamura et al., 2000, Wang et al., 2008). The CD6 molecule is a cell-
cell signaling and adhesion molecule (Singer et al., 2002, Whitney et al., 1995). The 
CD6 molecule has been suggested to play a role in apoptosis and positive selection 
of thymocytes in the thymus (Singer et al., 2002). 
TNFRSF1A encodes a major TNFα receptor that can activate NF-κβ, mediated 
apoptosis (Micheau and Tschopp, 2003), and regulate inflammation (Gimenez et al., 
2006). Mutations in TNFRSF1A have been reported to cause autosomal dominant 
familial Hibernian fever, or tumor necrosis factor receptor-associated periodic 
syndrome (TRAPS) (Ryan and Aksentijevich, 2009, Aksentijevich et al., 2001). A 
recent study found that 24% of MS patients (6 patients out of 24) with familial 
Hibernian fever-like symptoms carried the reported mutation (R92Q, rs4149584 A-
allele), and they could have been misdiagnosed with MS (Kumpfel et al., 2007). In 
general, the mutation was present in 4.7% of the MS cases and 3.0% of the healthy 
controls (Kumpfel et al., 2007). The rs4149584 A-allele frequency is reported to be 
4% in the CEU population, which could suggest that the familial Hibernian fever 
mutation might not be as penetrant or important to the disease as previously thought. 
Interestingly, familial Hibernian fever and MS both can have a relapsing-remitting 
disease course. Studies have shown that mice with no functional p55 
(TNFR1/Tnfrsf1a/CD120a) receptor were resistant to EAE and lenercept (a 
recombinant TNF receptor p55 immunoglobulin fusion protein) was able to block 
EAE in preclinical studies (Suvannavejh et al., 2000). In humans the effect was 
opposite, and patients treated with lenercept experienced symptom exacerbation, 
compared to patients treated with placebo (van Oosten et al., 1996, Group, 1999). 
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5.3 Accumulation of common MS associated alleles in 
Southern Ostrobothnia, Study III 
Current GWAS technologies have enabled the identification of over 50 common MS 
associated loci. Recent studies have observed an enrichment of a subset of these 
alleles both in MS patients, and especially in familial MS cases (De Jager et al., 
2009a, Gourraud et al., 2011, D'Netto et al., 2009). We used the method described 
by De Jager et al. to calculate an updated genetic burden score to assess the 
accumulation of common genetic variants in the Southern Ostrobothnian MS 
patients, compared to population samples and non-isolate cases. In addition to the 
regional analysis, we assessed the accumulation of genetic burden in multiplex 
families compared to sporadic cases and population samples. MS patients in general 
had a significantly higher genetic burden score compared to population samples. The 
phenomenon was statistically significant in all comparisons between MS cases and 
population samples, when all loci were included in the analysis (Figures 9 and 11). 
These findings were consistent with the previous studies (De Jager et al.1 2009a, 
Gourraud et al., 2011, D'Netto et al., 2009). 
5.3.1 Genetic burden score of MS associated alleles was not 
increased in the Southern Ostrobothian isolate 
The MS cases in the isolate and the non-isolate groups had, on average, a 
significantly higher genetic burden score compared to the population samples 
(Figure 6). Despite the two-fold increase in the prevalence and incidence of MS, the 
genetic burden score did not differ significantly between the 111 Southern 
Ostrobothnian MS cases (average 6.64±0.64) and the general 497 Finnish MS 
patients (average 6.77±0.62) (p=0.16)(Figure 6). Similarly, the 135 Southern 
Ostrobothnian population samples (average 6.31±0.61) were not significantly 
different from the 5399 general population controls (average 6.23±0.62) (p=0.18) 
(Figure 9). The number of samples was relatively small for the isolate groups. 
However, according to power calculations, we had 80% power (alpha 0.05) to detect 
a difference of 0.19 in the genetic burden score between the groups, and 90% power 
to detect a difference of 0.22 with the analyzed sample set. 
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Figure 9 Distribution of the genetic burden score by region. The y-axis indicates the genetic 
burden score, the median of each sample group is represented by a thick horizontal line, 
boxes indicate the middle 50% of the data points, and the whiskers indicate the 1.5×inter-
quartile range. The notches indicate the significance of the differences between the samples 
(±1.58 (interquartile range / √n):  non-overlapping notches suggest a significant difference. 
The differences between isolate and non-isolate samples were not significant. 
Therefore, we analyzed the interaction between affection status and the isolate 
region against genetic burden score. Affection status was significantly associated 
with the genetic burden score (p < 2×10-16) in linear regression analysis. In an 
additional linear model analysis of the Southern Ostrobothnian origin and affection 
status against the genetic burden score, the Southern Ostrobothnian origin was not 
significant (p=0.994). The multiplicative interaction analysis revealed that there was 
a borderline significant interaction between affection status and Southern 
Ostrobothnian origin (β=-0.211, se=0.841, p=0.0121), and that the genetic burden 
might in fact be reduced in isolate cases (Figure 9). It should be noted, however, that 
25% of the isolate cases in this analysis had a familial background compared to only 
7% of the non-isolate cases.  
The HLA locus is the best known MS locus and it was first discovered in 
families. When the HLA locus was excluded from the analysis, the genetic burden 
score in the Southern Ostrobothnian isolate cases decreased to the population level 
(Figure 10). Despite the limited power, it could be speculated that in the isolate 
region, most of the accumulated risk beyond the population level could be caused by 
the HLA region and potentially by as yet unknown, and possibly rare, MS loci. 
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Figure 10 Distribution of the genetic burden score without the HLA proxy SNP by region. The 
genetic burden score in MS samples from the isolate (1. MS SO) is close to both the isolate 
population level (2. Population SO) and general population level (4. Population), whereas the 
non-isolate MS cases (3. MS) have a significantly higher genetic burden score than all other 
samples. The y-axis indicates the genetic burden score, and the median of each sample 
group is represented by a thick horizontal line in the middle of the box. 
5.3.2 No evidence for accumulation of common MS associated alleles 
in Finnish multiplex families 
Analysis of the genetic burden score in sporadic MS cases, familial cases, and 
population samples was performed using the statistical program R 1.15.1. Sixty-three 
individuals with at least one relative with MS and 522 sporadic cases were included. 
Twenty-three cases reported a relative with MS, but were excluded due to an 
unconfirmed affection status of the reported relative. Both the sporadic MS cases 
(n=522, average=6.731, sd=0.621) and the familial cases (n=63, average=6.795, 
sd=0.636) were compared to each other and the general population sample (n=5534, 
average=6.230, sd=0.616), (Figure 11). Both non-familial and familial MS cases 
were significantly different from the population sample (p<2.2×10-16 and p=2.98×10-
7 respectively), (Figure 8). Unlike previous studies, we did not observe a significant 
difference between the familial and sporadic cases (p=0.216).  
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Figure 11 Distribution of the genetic burden score by familial background. The y-axis 
represents the genetic burden score. 
Since 28 (44%) of the 63 familial samples originated from the isolate, we plotted the 
familial cases according to their isolate status. There was a slight trend towards 
higher risk in the non-isolate familial cases, but the number of samples was too low 
to draw conclusions, and the difference was not statistically significant. No 
correlation was found with either affection status or family status in the regression 
analyses, and the number of samples was too small to conduct a combined analysis 
of isolate and familial status. 
A previous publication reported a significant difference of 0.27 in the genetic 
burden score between familial and sporadic cases (Gourraud et al., 2011). The 
difference observed in our study was much smaller, 0.064. Our sample size is small, 
but we had an estimated power of over 80% to detect a difference of 0.27. When we 
simulated a similar set of data using a difference of 0.27, and used the observed 
number of samples and standard deviations, only 0.8% of the 10,000 simulations 
produced a difference that was less than 0.065. This increases the likelihood that the 
lack of difference observed in our study may not just be due to small sample size and 
lack of power, but instead may indicate that the genetic burden might not be 
increased in the Southern Ostrobothnia. 
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6 CONCLUSIONS AND FUTURE 
PROSPECTS 
We have utilized the Finnish population structure, genome-wide methods, haplotype 
analysis and meta-analysis methods, to identify an association between STAT3 and 
MS in the Southern Ostrobothnian high-risk isolate population in Study I. Together 
with the replicated variants in TNFRSF1A, IRF8, and CD6 from Study II, the 
variants in STAT3, alongside the other currently known MS associated variants 
(n>50), are beginning to form a picture of immunological pathways that are relevant 
in certain cell types and might be affected by genetic variation that is relevant for 
MS (IMSGC, 2011, Maurano et al., 2012). The odds ratios for individual variants are 
modest and many associated SNPs lie outside of the coding regions of the genes, 
which is common for all complex diseases. Therefore, more studies are needed to 
identify causative functional variants and their role in MS disease pathogenesis. 
MS has an increased prevalence and incidence in the Southern Ostrobothnian 
isolate of Western Finland (Tienari et al., 2004). However, we could not find 
evidence for overall accumulation of common MS associated variants in this high-
risk isolate. Therefore, it is reasonable to hypothesize, that there could be population 
specific high-risk variants in the isolate region. The Finnish population structure, 
population history and isolate populations can be useful in gene mapping, especially 
of potential rare high-risk variants, and have been successfully used in mapping of 
monogenic Mendelian disorders (Tallila et al., 2009). The usefulness is not self 
evident in common complex diseases, although a recent study predicted a significant 
role for rare variants in complex diseases (Tallila et al., 2009). For example, 
although the increased prevalence of MS in Southern Ostrobothnia could be due to 
enrichment of rare genetic high-risk variants, it is not possible to exclude the effect 
of other factors, such as the environment. Another consideration is that if the 
predisposing genetic variants would have been enriched in the isolate, it seems 
reasonable to expect them to be enriched both in cases and in controls. Therefore, the 
odds ratio needs to be relatively large to provide enough power to detect such 
variants. One could hypothesize that this is possible in late-onset diseases, such as 
MS, if the variant does not significantly affect the number of offspring. Then, rare 
high-risk variants should be seen as familial aggregation. Indeed, there are several 
extended multiplex families with MS in Southern Ostrobothnia (Wikström et al., 
1984) and these families should be carefully studied in the future.  
Many studies use genome-wide genotyping chips to genotype common SNPs that 
are unlikely to have high odds ratios for common diseases and traits. On the other 
hand, searching for rare variants of importance by using common SNP genotypes is 
challenging. Imputation approaches have been developed, but they depend on 
previously identified variants, the observed population, the reference population, 
available genotype coverage, and they create genotypes with some degree of 
uncertainty. Another option to increase resolution could be a genome-wide haplotype 
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analysis, but also this approach would be limited by the observed genotypes and 
genotype combinations.  
The price for next generation sequencing is becoming affordable, and this 
technique can provide a way to directly measure most variation in individual 
genomes. There are already some examples, where studies have found rare likely 
causative de novo mutations using the NGS exome sequencing technology (Neale et 
al., 2012, O'Roak et al., 2012, Sanders et al., 2012). However, since most of the 
genome-wide hits in MS and other complex disorders lie outside protein coding 
regions, one could speculate that whole-genome sequencing might prove to be more 
informative than exome sequencing. So far, lack of functional annotation has 
hindered the interpretation of most variants outside coding regions, but annotations 
from the ENCODE project will likely improve this in the near future (Encode Project 
Consortium et al., 2012).  
Many MS associated SNPs are located in regulatory regions (Maurano et al., 
2012). For example, RNA sequencing in individuals who carry a potential risk allele 
or haplotype could give insights not only about the transcript levels, but also the 
transcribed isoforms. Since regulatory regions can be tissue specific (Dimas et al., 
2009, Djebali et al., 2012, Encode Project Consortium et al., 2012), the tissues of 
interest should be selected carefully, perhaps based on previous pathway analyses 
(Maurano et al., 2012, IMSGC, 2007).  
We have initiated targeted re-sequencing of the STAT3 locus in MS patients, 
aiming to identify variants that could explain the association signal. We have 
focused our attention to the individuals who carry the STAT3 risk haplotype. The 
verification or replication of identified candidate variants may, however, prove to be 
tricky. Especially variants that are private to a family, or a region, will require 
sophisticated analysis methods, large cohorts from potential isolate populations, and 
different functional studies. A study in large granular lymphocytic leukemia, which 
can have autoimmune disorder-like symptoms, has identified mutations in the 
STAT3 functional domain that were associated with phosphorylation status and 
activation (Koskela et al., 2012). Therefore, we are also planning to assess the 
phosphorylation status of STAT3 in MS patients and healthy individuals. 
Insight into the genetic etiology of complex diseases has increased significantly 
over the past few years. The work presented in this thesis has contributed to the 
collective knowledge and understanding of multiple sclerosis. Ultimately, these 
genetic studies will lead to the better comprehension of MS disease pathogenesis, 
biological disease mechanisms and to better treatment options. 
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